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A number of studies in the past decade consistently indicates that 
effectiveness of a variety of anti-cancer treatments, initially meant to directly 
inhibit tumor cell survival and proliferation, is actually based on immune 
system activation [1,  2]. Defined cytotoxic or genotoxic agents promote the 
generation of anticancer immune responses, potentially leading to tumor 
eradication, by inducing in malignant cells immunogenic cell death (ICD) [3]. 
The immunogenic characteristics of ICD are due to the mobilization of the so-
called damage-associated molecular patterns (DAMPs), like calreticulin and 
heat shock proteins (HSPs) exposure on the cell surface or ATP and high-
mobility group box 1 (HMGB1) release in the extracellular matrix [4]. Inside 
the cell, these molecules have mostly non-immunological functions, while 
when released on the extracellular environment or exposed on the cell surface, 
they act as both danger signals and adjuvant for the innate immune system [4]. 
The ability of different synthetic chemotherapeutic drugs to induce ICD 
has been characterized in detail [5]. In contrast, there is a paucity of data 
regarding natural products of potential clinical relevance [6]. A variety of 
natural anticancer compounds have been successfully characterized	 [7,  8]. 
However, their immunogenic potential has not been analyzed in comparable 
detail	[9]. 
In the following essay, the latest cancer research developments and their 
relationship with the immune system are explored, as well as the definition 
and characterization of ICD and the use of natural products in cancer research. 
The thesis is then divided into three distinct chapters, each covering one 
natural or semisynthetic product investigated for its ability to induce ICD in 
different cancer models. In particular, I provided a comprehensive preclinical, 
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in vitro study of cell death mechanisms and immunologic characteristics of two 
botanical drugs, Withania somnifera (WS) and Hemidesmus indicus (HI), and one 
isothiocyanate (ITC) derivative synthesized ad hoc in order to reach the ER, 
MG28. MG28 didn’t give the expected results and the study was interrupted, 
while both botanical drugs resulted able to trigger the main in vitro hallmarks 
of ICD. The most promising agent was HI. I demonstrated its ability to trigger 
oxidative and endoplasmic reticulum stress, two crucial events for the 
exploitation of ICD immunogenicity, then I proved its proficiency to positive 
modulate the expression and mobilization of characteristic DAMPs, including 
calreticulin, HSP70, ATP, and HMGB1 [5]. Prompted by these observations, I 
addressed HI’s ability to promote the activation of immature dendritic cells 
(iDC) and explored its immunomodulatory ability. Data consistently indicate 
that HI-treated tumor cell supernatants are able to promote the transition from 
an immature to a mature state of in vitro generated professional antigen-
presenting cell (APC). 
On the whole, the evidence reported in this thesis shows and confirms 
the remarkable potential of natural products in the oncological area and 
highlights their ability to induce ICD.  
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List of abbreviations 
 
2H4MBAC127  2- hydroxy-4-methoxybenzoic acid 
2H4MBAL  2- hydroxy-4-methoxybenzaldehyde 
3H4MBAL  3-hydroxy-4-methoxybenzaldehyde  
AIP1   Actin-interacting protein 1 
APC   Antigen presenting cells 
ASK1   Apoptosis signal-regulating kinase 1 
ATF6   Activating transcription factor 6 
Bcl-2   B-cell lymphoma 2 
Bip   Binding immunoglobulin protein 
BITC    Benzyl isothiocyanate 
CCCP   Carbonyl cyanide m-chlorophenyl hydrazone () 
CHOP   C/EBP homologous protein 
CLR   Calreticulin 
DAMP   Damage-associated molecoular patterns 
DC   Dendritic cell 
DCFDA   2′,7′-Dichlorofluorescin diacetate 
DCFDA   2′,7′-Dichlorofluorescin diacetate 
DHR   Dihydrorhodamine 
DHR    Dihydrorhodamine 
eIF2α   Eukaryotic initiation factor 2 alfa 
ER   Endoplasmic reticulum 
FCB   Flow Cytometry buffer 
FDA    Food and Drug Administration 
FHA    Fast Halo Assay  
GRP78   Endoplasmic reticulum luminal glucose-regulated protein 78 
GSH   Glutathione 
HI    Hemidesmus indicus 
HI    Hemidesmus indicus 
HID   Hemidesmus indicus decoction 
HMBA    2-hydroxy 4-methoxy benzoic acid 
HMGB1  	 High mobility group box 1 
HSP70   Heat shock protein 70 
HSP90   Heat Shock protein 90 
Hyp   Hypericin 
ICD   Immunigenic cell death 
iDC   Immature DC 
IRE1   Inositol-requiring protein 1 
ITC   Isothiocyanates 
JNK   c-Jun N-terminal kinase 
LOD   Limit Of Detection 
LOQ    Limit Of Quantification 
MAP   Mitogen-activated protein 
MAPKKK  Mitogen-activated protein kinase kinase kinase 
MEF   Mouse embryonic fibroblast 
MFI   Mean fluorescence intensity 
MLKL   Mixed lineage kinase domain-like protein 
MOMP    Mitochondria outer membrane permeabilization 
MUH   4-Methylumbelliferyl heptanoate 
NAC   n-acetyl cysteine 
Nrf2   Nuclear factor (erythroid-derived-2)-like 2  
NSF   Nuclear diffusion factor 
p- eIF2α   	 Phosphorylated	eukaryotic initiation factor 2 alfa 
p-PERK   Phosphorylated	PKR-like endoplasmic reticulum kinase 
PAMP   Pathogen-associated molecular pattern 
PARP   Poli ADP-riboso polymerase 
PBMC   Total peripheral blood mononuclear cells 
PEITC    Phenethyl isothiocyanate 
PERK   PKR-like endoplasmic reticulum kinase 
PRR   Pattern recognition receptors 
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RCD   Regulated cell death 
RFP    Red fluorescent protein 
RIPK1   Receptor-interacting serine/threonine-protein kinase 1 
RIPK3   Receptor-interacting serine/threonine-protein kinase 3 
SFN    Sulforaphane  
TAA   Tumor associated antigen 
TLR   Toll	like	receptors 
TNF   Tumor necrosis factor 
TRAF2   Tumor necrosis factor receptor-associated factor 2 
TUDCA  	 Sodium tauroursodeoxycholate 
UPR   Unfolded protein response 
WDA   Witanolide A 
WDB   Witanolide B 
WFA   Witaferin A 
WS   Withania somnifera 
WSDE    Withania somnifera DSMO extract 






 Cancer is the second leading cause of death among non-communicable 
diseases worldwide [10]. Carcinogenesis is a multifactorial and a multistep 
process. Sequential acquisition of specific mutations in key genes (oncogenes) 
is the cause of the ruthless transformation from normal to tumor cells. Thus, 
tumor cells acquire peculiar common abilities that reflect DNA mutations and 
enable cancer cells to survive, proliferate and differentiate. The hallmarks of 
cancer consist of: proliferative signaling sustain, growth suppressors evasion, 
cell death resistance, replicative immortality, angiogenesis, invasion and 
metastasis activation, energy metabolism reprogramming, and immune 
evasion (Figure 1.1) [11]. 
 
Figure 1.1 The hallmarks of cancer proposed by Douglas Hanahan and Robert A. Weinberg©	[11]. 
 
As a consequence of the remarkable progress in the knowledge of cancer 
biology, effective antitumor strategies have been developed. It’s now been 
almost 80 years since a patient afflicted by cancer was successfully treated with 
a chemotherapeutic agent (nitrogen mustards) for the first time [12]. Since 
therapies. For example, the deployment of apoptosis-inducing
drugs may induce cancer cells to hyperactivate mitogenic
signaling, enabling them to compensate for the initial attrition
triggered by such treatments. Such considerations suggest
that drug development and the design of treatment protocols
will benefit from incorporating the concepts of functionally
discrete hallmark capabilities and of the multiple biochemical
pathways involved in supporting each of them. Thus, in partic-
ular, we can envisage that selective cotargeting of multiple
core and emerging hallmark capabilities and enabling character-
istics (Figure 6 ) in mechanism-guided combinations will result in
more effective and durable therapies for human cancer.
CONCLUSION AND FUTURE VISION
We have sought here to revisit, refine, and extend the concept of
cancer hallmarks, which has provided a useful conceptual
framework for understanding the complex biology of cancer.
The six acquired capabilities—the hallmarks of cancer—have
stood the test of time as being integral components of most
forms of cancer. Further refinement of these organizing princi-
ples will surely come in the foreseeable future, continuing the
remarkable conceptual progress of the last decade.
Looking ahead, we envision significant advances during the
coming decade in our understanding of invasion andmetastasis.
Similarly, the role of aerobic glycolysis in malignant growth will
be elucidated, including a resolution of whether this metabolic
reprogramming is a discrete capability separable from the core
hallmark of chronically sustained proliferation. We remain
perplexed as to whether immune surveillance is a barrier that
virtually all tumors must circumvent, or only an idiosyncrasy of
an especially immunogenic subset of them; this issue too will
be resolved in one way or another.
Yet other areas are currently in rapid flux. In recent years, elab-
orate molecular mechanisms controlling transcription through
chromatin modifications have been uncovered, and there are
Figure 6. Therapeutic Targeti g of the Hallmarks of Canc r
Drugs that interfere with each of the acquired capabilities necessary for tumor growth and progression have been developed and are in clinical trials or in some
cases approved for clinical use in treating certain forms of human cancer. Additionally, the investigational drugs are being developed to target each of the
enabling characteristics and emerging hallmarks depicted in Figure 3 , wh ch also hold promis as cancer thera eutics. The drugs listed are but illustrative
examples; there is a deep pipeline of candidate drugs with different molecular targets and modes of action in development for most of these hallmarks.
668 Cell 144, March 4, 2011 ª2011 Elsevier Inc.
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then, cancer research has come a long way and was able to find cures for 
Hodgkin disease, childhood acute lymphoblastic leukemia (the 1960s) and 
testicular cancer (the 1970s), as well as discovering methods to manage many 
other types of cancer [13]. However, cancer is still a huge burden on 
populations worldwide. Even at present, an average of 4600 new patients are 
being diagnosed with cancer on a daily basis in the United States of America 
and about 1650 of them won’t survive [14]. Colorectal cancer is the third most 
common cancer diagnosed among the entire population and American Cancer 
Society expected to be the second cause of death among all type of cancer in 
2017 in the USA, second only to lung cancer, hypothesizing 50260 victims 
(Figure 1.2 A and B). It has been demonstrated that incidence rates increase 
with age for the majority of tumors [10]. This notion is intuitive since it 
basically reveals cell DNA damages gathered over time. At the same time, it 
can suggest that different groups of population can be affected in a different 
way from different types of tumor, depending on the age. Pursuing this 
assumption, it turns out that colorectal cancer is still a burden for the older 
population (Figure 1.2 D), but it doesn’t affect children from 0 to 14 years old 
[10]. In this part of the population the biggest burden is represented by 
leukemia, which is responsible for the 35% of deaths among all type of cancers 
[10] (Figure 1.2 C). Thus, both colorectal and leukemia neoplasms affect two 
sensitive part of the population and whether mortality trend is descending in 
both cases [10], any exhaustive cure has not been discovered yet and the limit 
of currently chemotherapy is still causing too many victims. 
 Resistance to cancer therapies and immunoevasive characteristics of 
tumor cells are two of the major problems that preclude the success of 
antitumor strategies [15]. For a long time, research has focused on exploring 
new approaches that implied a complete tumor eradication coupled with 
increased sensitivity to chemotherapy or the immunological identification by 
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the immune system of low immunogenic tumors cells [16]. Thus, a therapeutic 
approach that combines these two stratagems would determine long-term 
success of anticancer therapies. In this context, immunogenic cell death (ICD), 
which is a regulated form of cell death capable of exerting immune 
stimulation, represents the link between tumor demise and recruitment of the 
immune system. 
 On the other hand, it has been reported that in the past few years nature 
has become the most productive source of drug leads in the pharmaceutical 
field, with more than 100 new natural products currently being studied in 
clinical trials. Particularly, it represents a very interesting and prosperous 
source of compounds with antitumor potential, emphasized by the fact that 
cancer is the major recipient among all pathologies for the use of these drugs 
[17] . 
Figure 1.2 Estimated deaths for 2017, by cancer type, both sexes combined-Copyright © 2017 
American Cancer Society (A), estimated percentage of cancer death all ages (B) 0-14 years old (C) 65+ 































































































I.I Cancer and Immune System 
 Ideally, the immune system should be able to identify and eradicate 
cancer cell precursors, avoiding the development of relevant tumors in the first 
place [15]. However, one of the hallmarks of tumors is exactly the ability to 
escape immunosurveillance. Immunosuppressive microenvironment or other 
common characteristics that participate in carcinogenesis, like the presence of 
hypoxic area, can be indirect causes of this phenomenon.  
In addition, cancer cells themselves have many weapons to their disposal. 
During each phase of the tumorigenic process, an intense crosstalk between 
cancer cells and intrinsic (cell to cell) or extrinsic (cell to host immune system) 
elements make them achieve the capability of neglecting the host’s immune 
system. Initially, tumors elicit an –albeit transient- immune response, that is 
insufficient to nip carcinogenesis in the bud. Later on, tumor cells face 
immunoselection. This means that the established pre-malignant lesions 
consist of the highest mutagenic cell fraction that was able to escape the 
surveillance of the immune system as a result of its intrinsic nature or, again, 
due to the ineffective immune response that in turn was caused by the 
induction of tumor-antigen specific immune tolerance [15]. Then, after the full-
blown tumor is formed, immunosubversion — the active suppression of 
immune response — could annihilate both innate and adaptive immune 
responses [15]. 
Thus, overtaking the immunoevasive phenotype of tumor cells to 
increase their immunogenic potential represents a very promising strategy for 
effective cancer treatment [18]. In particular, this strategy embraces the 
purpose of eradicating all neoplastic lesions and preventing any possible 
relapse through the acquisition of an adaptive immune memory against tumor 
cells. Many interesting immune-therapies engage a direct stimulation of 
autologous or innate immune cells or retrieve T cells effector activity. Such 
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therapies are, for example, dendritic cells (DCs)-based vaccines, immune 
checkpoint blockers and adoptive T-cells transfer. However, an autologous 
stimulation of DCs, where the demising tumor cells themselves exert the 
imprinting to the adaptive immune system, in an “endogenous vaccine”-like 
effect, could be more efficient in long term cancer eradication. In this context, 
ICD is the antitumor strategy that provides the implant for this kind of 
immunity.  
 In this regard, in order to understand how dying cells can trigger ICD, it 
is necessary to take a step back and understand how the immune system 
relates to the surrounding stimuli. For a long time, the immune system was 
described through the self/non-self model. Briefly, all molecules that come into 
contact with the immune system of a certain organism were categorized 
depending on whether they belong to that organism or not. To clarify, the 
organism’s own cells and cellular antigens (self-antigens) were included in the 
self-category, while pathogens, viruses, bacteria and anything which had an 
extraneous origin to the organism and possessed non self-antigens was 
considered non-self (Figure 1.3). According to this model, self and non-self 
stimuli respectively inhibited or triggered the immune response through the 
interaction with the pattern recognition receptors (PRRs) that are expressed on 
immune cells [19,  20]. The “non-self” category is in turn subcategorized and 
includes “microbial-like non-self”, “missing self” or “induced or altered self”. 
In the case of microbial invasion, the activation of PRRs lies on the pathogen-
associated molecular patterns (PAMPs) that are biological components of the 
invaders, such as the lipopolysaccharide of gram-negative bacteria or the 
DNA/RNA-based genome of viruses. The “missing self” refers to the loss or 
downregulation of outer membrane molecules, such as the “don’t eat me” 
signal CD47, while the “altered self” indicates the detection of abnormalities 
such as the transformation that normal cells incur after viral infections [20]. So, 
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according to the self/non-self theory, only these three categories are able to 
trigger the PRRs and to prompt the immune response. However, the 
limitations of this theory become apparent when the immunogenicity of dying 
cells is envisaged. Indeed, the self/non-self theory considers both necrosis and 
apoptosis silent or tolerogenic processes. According to this theory, phagocytes 
remove apoptotic cells without eliciting any immune response in a way that 
could also lead to tolerogenicity. Following the same rationale, the necrosis-
driven inflammation favors tissue repair processes instead of immunity, even 
if currently it’s accepted that tissue repair is largely mediated by the immune 
system [20]. Moreover, the concept of Tumor-Associated Antigens (TAA) is 
not coherent with this schematic explanation of immune system. In fact, 
immune system recognizes TAA, but they cannot be considered either non-
self, missing self or altered self [21]. To explain these discrepancies, the 
self/non-self model was molded into the danger model of immunity. In this 
scenario the immunological recognition does not rely on the discrimination 
between self and non-self entities but, regardless from the source, it 
distinguishes safe or dangerous stimuli [19,  22]. These dangerous entities alert 
the immune system through the emission of danger signals and alarmins that 
can be released, for example, by dying cells and are called damage-associated 
molecular patterns (DAMPs). DAMPs resemble to endogenous PAMPs and 
share with them the PRRs [19]. Indeed, the danger model embraces a larger 
spectrum of molecules that can be considered dangerous and can activate an 
immune response. For example, starting from pathogens arriving to wound or 
necrotic tissue, from diseased cells to cells undergoing non-physiological 
death, they all are immunogenic entities [19]. This new model of immunity 
also explains how self-cells in sterile conditions are able to stimulate an 
immune response if properly stimulated, and paved the way for the 






Figure 1.3 Schematic representation of Self-nonself theory versus Danger theory 
 
Another very common pitfall parallel to the self/non-self model of 
immunity was to strictly categorize cell death routes into two closed classes: a 
not regulated, pathologic and inflammatory cell death (necrosis), and a form of 
regulated, physiological, not immunogenic or tolerogenic ones (apoptosis). 
This outdated and wrong concept prevailed for a long time, but now it’s clear 
that these sharp-cut differences do not exist. On the contrary, cells can decease 
after the activation of a genetically programmed molecular pathway in a 
necrotic morphological way and, at the same time, apoptotic cells are able to 
activate an antigen immune response [23]. More specifically, according to the 
immunological effect and the contingent activation of TAA-targeted immunity, 
three distinct profiles of cancer cell death can be triggered depending on the 





















inflammatory cell death. As the name suggests, tolerogenic cell death is the 
physiological or homeostatic kind of cell demise that produces the active 
suppression of the immunity through the deliverance of anti-inflammatory 
factors [21]. At the other extreme, ICD is a non-homeostatic kind of cell death 
[25], which produces proinflammatory cytokines and chemokines as a result of 
DAMPs release and that culminates in the immunostimulatory phagocytosis of 
apoptotic corpses [26]. Inflammatory cell death occurs when indistinct 
immune responses induced by a plethora of tolerogenic and immunogenic 
signals are elicited and culminate in acute reactions [27].  
Thus, apoptosis can be either tolerogenic or immunogenic whether is 
physiological or triggered by ICD inducers, respectively [21]; necroptosis can 
be both immunogenic and inflammatory [27] and non- programmed necrosis 
is considered strictly inflammatory [28]. 
I.II Immunogenic Cell Death as Anticancer Strategy 
 The concept of ICD was proposed for the first time after the danger 
model of immunity was developed and it was clear that regulated forms of cell 
death (RCDs) (i.e. apoptosis, necroptosis, etc) could be immunogenic instead of 
immunological silent or tolerogenic, depending on the initiating stimuli [25]. So 
far, several chemotherapeutic agents — both physical and chemical — were 
identified as bona fide ICD inducers. Doxorubicin, oxalilplatin and the 
hypericin-based photodynamic therapy (Hyp-PDT) are all examples of ICD 
promoters. It’s impossible to find similarities among them in their mechanism 
of action or molecular structure but apparently they all induce ICD, acting 
through a different interpretation of the same pathway. Two crucial events are 
essential to trigger immunogenic apoptosis: endoplasmic reticulum (ER) and 
oxidative stress.  
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 ER is a fundamental organelle for eukaryotic cells. It regulates lipid 
biosynthesis, calcium ion (Ca2+) storage, and synthesis, modification and 
folding of proteins that are designed to be released or incorporated into the 
plasma membranes [29]. 
Three major sensors — PKR-like ER kinase (PERK), inositol-requiring 
protein 1 (IRE1) and activation of transcription factor 6 (ATF6) — constitute 
the unfolded protein response (UPR) and are in charge for ensuring that 
homeostatic conditions are maintained. Normally, they are coupled with 
binding immunoglobulin protein/ ER luminal glucose-regulated protein 78 
(Bip/GRP78) to form an inhibitory complex that unties in condition of stress. In 
this situation Bip gains the function of chaperon with rescue activities in order 
to restore ER homeostasis and at the same time make the three sensors free to 
activate the UPR. If stress conditions are not severe, the UPR is able to 
reestablish cellular integrity: PERK phosphorylates its main downstream 
protein eukaryotic initiation factor 2 alpha (eIF2α), which in turn slows down 
protein synthesis and reduces the load of incoming naïve proteins. At the same 
time, it stimulates Ca2+ preservation while IRE1 and ATF6 allow transcription 
of x-box binding protein 1 (XBP1), which ensures the prevention of the 
aggregation of unfolded proteins. This fast response enables the cells to restore 
homeostasis. However, if stress is prolonged or too severe, the balance is 
tipped toward pro-death signals. In this case, different pathways can trigger 
apoptosis. IRE1-tumor necrosis factor (TNF) receptor-associated factor 2 
(TRAF2)-c-Jun N-terminal kinase (JNK) pathway could elicit apoptosis 
through the interaction with the mitogen-activated protein (MAP) kinase 
kinase kinase (MAPKKK), apoptosis signal-regulating kinase 1 (ASK1) and its 
activator actin-interacting protein 1 (AIP1), or through the involvement of the 
proapoptotic B-cell lymphoma 2 (Bcl-2) family members that in turn amplify 
IRE1 signal [30]. In addition, PERK is able to upregulate C/EBP 
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homologous protein (CHOP) which in turn downregulates the anti-apoptotic 
protein Bcl-2 and activates the transcription of ER-Oxidase 1α, which is an 
apoptosis effector [30]. So far, it has been demonstrated that while all UPR 
sensors are activated during ICD, only the activation of PERK is mandatory to 
elicit immunogenicity [31]. 
 ICD-inducing agents elicit a form of ER and oxidative stress that 
activate a danger pathway which involves the mobilization of the ICD 
mediators, the so-called DAMPs. As above mentioned, DAMPs are 
endogenous molecules that acquire immunostimulant properties when 
exposed on the outer cellular membrane or released in the extracellular matrix, 
in a defined spatial-temporal manner that differs on which agent/stimulus 
started the process. When exposed or liberated to the cellular matrix by 
damaged or dying cells, DAMPs bind PRRs directly on the surface of immune 
cells, such as different types of toll like receptors (TLR’s), creating a bond 
between the demising cancer cells and the immune system [31]. In other 
words, they turn in “eat me” or “find me” signals for antigen presenting cells 
(APC), like DCs, macrophages, certain T-cells, or natural killer (NK) cells. 
Moreover, they foster DCs maturation and the activation, elaboration and 
presentation of the TAA to immature lymphocytes T. In this way, the host 
immune system established the first contact with the specific TAA and a 
subsequent stimulation of TAA-specific T-cell-mediated immune responses 
would result into the eradication of the remaining cancer cells together with an 
immunological memory [4]. In this way, the adaptive immunity is triggered 
and the treatment of the tumor resulted in an endogenous vaccine-like effect 
(Figure 1.4). Furthermore, DAMPs sustain the opsonization of dying cancer 
cells and foster the activation of inflammatory processes dependent on the 






Figure 1.4 Schematic representation of the immunogenic cell death (ICD) pathway. 
I.III Anticancer Therapy triggers ICD through different 
Regulated Forms of Cancer Death 
 The concept of ICD is usually used as synonym for immunogenic 
apoptosis. However, other pathways may potentially lead to the immunogenic 
stimulation.  
 Among all RCDs, apoptosis is the most renowned and is mediated by 
effector caspases. Three main pathways are able to initiate this process. The 
extrinsic or receptor-mediated via, which foresees the activation of death 
receptors on the outer cell surface that leads to the activation of caspase 8 [33]; 
the intrinsic or mitochondrial pathway, which releases cytochrome c and 
allows the activation of the effector caspases 3 and 7 [33]; the ER pathway that 
was examined in detail in the last paragraph, which foresees the activation of 
executor caspases 3, 6 and 7 [30]. Morphologically and functionally, apoptosis 































phosphatidylserine on the outer leaflet of the plasma membrane during the 
early stages, chromatin condensation, intranucleus DNA cleavage and 
cytoplasmic membrane blebbing, while keeping cellular integrity. All these 
events prevent cells from losing all their content like during necrosis [34]. Once 
immunogenic apoptosis is triggered, DAMPs trafficking involves all the 
apoptotic phases, from the very early to late stages. For example, during the 
early phases of apoptosis, the ER chaperone calreticulin (CLR), heat shock 
protein (HSP)-70/90 are exposed on the outer surface of the cells, recognized 
by the CD91 receptors and act as eat-me signals inducing the engulfment of 
dying cancer cells [35,  36]. ATP can be released actively or passively during 
the pre-apoptotic or early- to mid-apoptotic phases respectively, and could 
represent either a potent short-range find-me signal for attracting monocytes or 
as a proinflammatory molecule by binding the P2Y2 purino-receptors, or the 
P2X7 receptor on innate immune cells [32]. During the late phase of apoptosis 
the most important DAMP is the high mobility group box 1 (HMGB1). When it 
is released, it binds TLR2 and TLR4 on DCs, stimulating production of 
proinflammatory cytokines and assisting in the proper antigen presentation 
[37]. 
 Necrosis, on the other hand, is a non-regulated form of cell death, in 
which cell membranes become permeable during the early phases of the 
process and release all the cytoplasmic material and induce an inflammatory 
response. However, it’s not completely true that this uncontrolled pouring of 
cytoplasmic material is able to trigger a complete immune response. Certainly, 
the same DAMPs mobilized during apoptotic immunogenic cell death are 
released in the extracellular matrix, but the lack of spatial-temporal 
arrangement of this process could decrease its immunogenic potential. 
Additionally, during necrosis many other substances are infused outside the 
cells and quench the immunogenic potential of the emitted DAMPs [23]. 
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This means that the mere disassembly of plasma membrane and the flow of 
the cytoplasmic content into the microenvironment are not sufficient to induce 
ICD. This statement is supported by different in vitro and in vivo experiments. 
In vitro experiments showed that mouse cancer cells undergoing necrosis via 
boiling or freeze–thawing cycles do not activate DCs [38], nor are tumor 
necrotic cells able to stimulate protective immune response after repeated 
inoculations of syngeneic mice [39]. Accordingly, TC-1 cells undergoing 
accidental necrosis do not efficiently vaccinate syngeneic C57BL/6 against a 
successive inoculation of living cells of the same type [40], as opposed to cells 
undergoing through the regulated form of necrosis, i.e. necroptosis [40]. 
Necroptosis is a caspase-independent form of RCD. It is initiated by 
death receptors ligands’ activation, which in turn activates the kinase activity 
of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), which 
mediates the RIPK3 and mixed lineage kinase domain-like protein (MLKL) 
activation, the downstream mediators of necroptosis. The morphological 
changes during necroptosis correspond to those of necrosis, thus its pro-
inflammatory activity is still significant. However, unlike necrosis, a pattern in 
DAMPs mobilization has been discovered. Necroptotic TC-1 and EL4 cells 
show ecto-CLR, ATP secretion and HMGB1 release only in absence of RIPK3 
and MLKL knock-out conditions [40], which means that DAMPs pattern is 
triggered only when the necroptotic machinery is working. Moreover, recently 
it has been attested that at least part of the immunogenicity triggered by the 
bona fide ICD inducer mitoxantron relies in its capability to trigger necroptosis. 
In fact, necroptotic TC-1 cells treated with mitoxantron elicited protective 
immunity in C57BL/6 only in the presence of active RIPK3 and MLKL. This 
behavior has been linked to the inability to secrete ATP and release HMGB1 
when necroptosis doesn’t subsist [40]. What’s more, unlike wild-type, RIP3 
and MLKL null TC-1 cells growing on C57BL/6 mice are less sensitive to the 
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direct antitumor effect of mitoxantron and after the treatment the 
microenvironment is less rich in CD11c+-CD86+ APCs and CD8+ T cells [40]. 
Surprisingly, the mechanisms that underline the immunogenicity of ICD seem 
to be different if this process is triggered by necroptosis or apoptosis. A very 
recent study showed that necroptotic cell death promoted ICD in CT26 cells in 
an UPR-unrelated way, infusing the idea that necroptotic ICD could be a 
complete distinctive form of apoptotic immunogenic death [39]. 
More, autophagy has recently been added as additional engine which 
drives the immunogenicity of ICD. [41]. Properly, autophagy is a defense 
mechanism triggered in response to a different kind of stress, such as a lack of 
nutrients or energy, bacterial infections or damaged intracellular organelles. It 
is a multistep self-degradation process, where cytoplasmic material is 
sequestered into phospholipidic membranes to form autophagosomes. These 
vesicles are then fused with lysosomes and degraded by lysosomal hydrolases 
with the aim of gaining energy from these anabolic reactions. Kroemer’s group 
noticed that during drug-induced autophagy, cells were able to release ATP 
and demonstrated that the autophagic process is also required, but not 
sufficient, to optimally spark pharmacologically induced immunogenicity [25]. 
In fact, inhibiting autophagy by blocking different nodes of the autophagic 
machinery leads dying cells to significantly impair ATP release that in vivo 
translates into a lesser enrollment of DCs, macrophages and monocytes and 
lacking antitumor immune responses and therapeutic failure [42]. Indeed, 
coupling autophagy inhibitors to the ATP degradation enzyme inhibitor 
ectonucleotidase restored normal ATP levels and the related immunogenicity 
[42]. It’s worth mentioning that many tumors are characterized by defects in 
the autophagic process and that may reveal at least one way through which 
tumors escape from immunosurveillance [41]. 
 Other forms of RCD, such as ferroptosis, seem capable to trigger ICD 
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[31], however, the limited literature data available on this topic makes an 
extensive survey impossible at this time. 
 Currently, almost no anticancer drug elicits its antitumor potential 
through the activation of only one cell death mechanism, and these 
observations give promising indications about a synergistic strategy, which 
could involve the associations of different variants of ICD to induce a more 
efficient immune response. But attention must be kept when consistent 
necrosis fosters other RCDs. 
  
 For simplification purposes from this point on, every time ICD will be 
mentioned it will refer to the apoptotic form, unless specified differently. 
I.IV Type I and II Inducers of ICD 
 As mentioned above, the two compelling events necessary to elicit ICD 
are ER and oxidative stress. Each ICD inducer elicits ER stress in a different 
way and this translates into different DAMPs trafficking in terms of spatio-
temporal release during the death process, composition patterns and/or entity 
[29]. Accordingly, the way ROS levels and ER stress are related mirrors the 
different immunogenic outcome. On this basis, two broad groups of ICD 
inducers have been identified: type I and type II. 
 Type I inducers comprehend all those compounds which the main 
proapoptotic “on target” effect doesn’t involve ER, thus provoking ICD-related 
immunogenicity via “off target” ER stress. ER stress can be induced by 
mitochondrial ROS, as it happens in the case of cardiac glycosides and 
wogonin [4,  43-45]. In this case, ROS are transferred from the mitochondria to 
the ER through the mitochondria-associated ER membranes (MAMs) [46] and 
there they exert the stress. Doxorubicin and mitoxantrone are two other type-I-
ICD inducers. Their mechanism of action requires the interaction with lipid 
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membrane, thus with ER lipid membrane too, which results in ROS-related 
lipid peroxidation and consequent ER stress [4,  43,  44,  47]. Another 
subfamily of ICD type I inducers acts through direct or indirect unfolded 
protein overload, which only causes ROS production in a second phase. 
Shikonin and bortezomib fall into this category [4,  25].  
Type II inducers, on the contrary, induce immunogenic apoptosis 
orchestrating danger and apoptotic signaling on the same “on target” ROS-
based ER stress. In this way, oxidative stress that originates in the ER can be 
amplified to the mitochondria and the lipid membrane in an opposite direction 
as mentioned above. Currently, the only chemotherapeutic agent able to elicit 
ICD in a type I manner is the Hyp-PDT. Hyp localizes in the ER and when 
activated with the proper wavelength evokes a strong ROS production that 
also activates the UPR response [46,  48]. 
Of note, other treatments outside the strict chemotherapeutic category, 
such as oncolytic viruses (e.g., Newcastle disease virus) [49,  50] and platinum 
II–N-heterocyclic carbene complexes [51], have been identified as type I ICD 
inducers. 
Due to the greater amount and promptness of the mobilization of 
DAMPs induced by type II agents, it’s clear that the quality of ER stress 
elicited generates a better immunological profile than type I [4]. Furthermore, 
type I and II differ in the role of PERK. In type I inducers, it regulates the 
canonical UPR pathway via eIF2α, while in type II it regulates the expansion of 
the secretory pathway in an unknown way. But not enough is known to 
unravel key mechanisms underlying these differences. 
 Usually, every ICD inducer is characterized by its own pattern of 
DAMPs, in terms of quality (type of DAMPs and how they are mobilized), 
quantity and release/exposure kinetic depending on the ER stress provoked 
[29]. Furthermore, besides DAMPs emission, cancer cells themselves can 
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stimulate the immune system if triggered by ICD inducers. In this case, dying 
cells typically trigger the host’s defense response in the same manner as 
pathogens or viral infection trigger the so-called “altered-self mimicry” [31]. 
For instance, cells dying through ICD can mediate the chemokine (C–X–C 
motif) ligand 1 (CXCL1), chemokine (C–C motif) ligand 2 (CCL2) and CXCL10 
release, which directly attracts neutrophils in a way that reminds the response 
of bacterial or viral infections. Through respiratory burst, the neutrophils will 
then direct anticancer cytotoxicity against the remaining cancer cells [52]. 
I.V ICD and Drug Discovery 
 As above reiterated, ICD inducers do not have a structure-activity 
relationship or common biochemical features, but they definitely follow some 
patterns that are still unknown. Indeed, the incapability to prompt enough 
amount of stress underlying the mobilization of DAMPs or the mere inability 
to promote the mobilization of a single DAMP is enough to compromise all the 
immunogenicity of the treatment [23]. The most fitting example of this issue 
refers to the ICD inducer oxaliplatin and the immunogenic null cisplatin. They 
both are DNA alkylating agents but only oxaliplatin targets the UPR and 
promotes CLR exposure to the outer membrane of damaged or dying cells [53]. 
By consequence, unlike oxaliplatin-treated cells, cisplatin-treated mouse cancer 
cells are not able to vaccinate syngeneic hosts. Only the combined treatment 
with an ER stressor, such as thapsigargin or tunicamycin, is able to restore the 
immunogenicity of cisplatin [53]. 
Even trickier is the example of cardiac glycosides which in vitro induce 
CLR exposure, ATP secretion and HMGB1 release, but are not able to create an 
immunological memory in mice via antigen-specific response [54]. This 
behavior suggests that new and more significant DAMPs have yet to be 
identified, and confirms that so far the prediction of the immunogenicity of 
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a cell death cannot rely solely on the DAMPs’ analysis. These discrepancies 
underline the importance of vaccination assays, but at the same time raise the 
issue of translational experiments on human cancer models, since vaccination 
is not an option. While waiting for humanized mice to give a syngeneic model 
of human tumorigenesis, valid alternatives are in vitro study on DC maturation 
[23].  
To conclude, if possible, tumor heterogeneity and the not fully 
understood mechanism of action of ICD inducers make the process of drug 




II. Natural Products in Cancer 
Therapy 
From ancient times, plants have been used as a source of remedies for the 
most diverse pathologies, and even today they keep on representing the 
richest library of drug leads for the discovery of new medicines. They play a 
pivotal role in anticancer therapy and they usually show a more favorable 
profile than newly synthesized chemical compounds, in terms of 
bioavailability and low toxicity [55]. The relevance of natural compounds in 
cancer research is confirmed by statistics. Between 1999 and 2008, 36% of the 
first-in-class small molecules approved by the US Food and Drug 
Administration (FDA) for cancer treatment were natural products or natural 
product derivatives [56]. Moreover, from 2004 to 2014, 28 of 70 antitumor 
drugs originating from natural products have been approved, while the others 
were in phase 1 (14), 2 (19) or 3 (9) of clinical trials at the end of 2014, 
respectively [55] underlying the proficiency of these products in the field of 
cancer treatment. 
Natural products can be categorized in single molecules (phytochemicals) 
or botanical drugs. FDA defines botanical drugs as “products that consist of 
vegetable materials, which may include plant materials, algae, macroscopic 
fungi, or combinations thereof, intended for a use in the diagnosis, cure, 
mitigation, treatment or prevention of disease in humans” [57]. They contain a 
combination of potential active compounds that together exert the biologic 
activity. Intuitively, the complex composition of botanical drugs mirrors their 
capability to affect more than one biological pathway, which in turn results in 
a wider global activity. Actually, in vitro and animal studies documented that 
both phytochemicals and botanical drugs share the significant pleiotropic 
mechanism of action that makes them able to simultaneously target 
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multiple hallmarks of diseases, thus increasing the chances to beat complex 
pathologies such as cancer [58]. 
On the other hand, as a consequence of their complex intrinsic nature, 
botanical drugs offer more challenges than purified phytochemicals in terms of 
drug development process. In fact, even if safety and toxicity are usually not 
crucial problems since botanical drugs have frequently been used in traditional 
medicine and they’re commonly available as dietary supplements, batch-to-
batch differences in composition could affect the biological effects. Indeed, the 
weather, seasonal variations and geographical location are some of the 
elements that could affect the intrinsic composition of the growing plant. Thus, 
to guarantee quality, botanical drugs routine analyses are more complex than 
those necessary for high-purified drugs (phytochemicals or synthetic 
molecules indiscriminately) [59]. Quality controls concern all the phases of 
botanical drug production. For instance, before the harvesting, raw materials 
in the field are checked and both chromatographic analyses and biological 
assays are necessary for the quantification of the components and the control 
of pharmacological consistency [59]. In this context, a useful habit could be to 
assess the exact chemical composition of botanical drugs, in order to draw a 
comprehensive “fingerprint” of these substances. Then, marker compounds 
would be used to rapidly and unambiguously check batch consistency. 
 To date, the FDA approved two botanical drugs as prescription 
medicines for the market: Veregen, a water extract of green tea leaves obtained 
from Camelia sinensis and used to topically treat external genital and perianal 
warts, and Crofelemer (also known as Fulyzaq or Mytesi), obtained from the 
latex of the South American tree Croton lechleri, indicated for the oral 
symptomatic treatment of HIV/AIDS-related diarrhea on patient going 
through antiretroviral therapy. Still, no cancer treatment has been approved, 
but the number of submissions is rapidly escalating and it won’t be long until 
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CHAPTER 1. Withania Somnifera 
1.1. Introduction 
Name: Withania somnifera - Ashwagandha 
Family: Solanaceae 
Genus: Withania 
Species: Whitania somnifera (L.) Dunal 
Geographical origin: India, South Africa, 





Withania somnifera (WS), better known as Ashwagandha or Indian winter 
cherry for the characteristic shape of its fruits, is a plant used in Ayurvedic 
medicine from ancient time. Before the intense cultivation in India, it was 
frequent spread in the dry and warmest Mediterranean areas, like Italy (Sicily 
and Sardinia), in the tropical regions of Africa and South Africa, Cape Verde 
island, Arabia and, of course, Middle East areas, like India, Sri Lanka and 
China [60]. 
WS is an evergreen, erect shrub that can achieve 150 cm in height. The 
petiolate leafs are ovate or elliptic-ovate, acute to obtuse at the apex and 
oblique at the base, covered by grey tomentum (pubescence). Large and small 
leafs alternate on the vegetative shoots in a way that floral branches are 
opposed to the large leafs. The axil embraces cluster of cymose of 4-25 pale 
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monoceous flowers [61]. Flowers blossom during spring, they are sessile and 
form axillar clusters. The white-yellow corolla is composed by lanceolate lobes 
while the calyx expand around the reddish fruit. Fruits are small orange-red 
berry-shaped and carry abundant seeds [62]. Roots are long about 15 cm and 
have an average diameter of 12 mm. They are cylindrical, light yellow-
brownish, and taper down at the lower extremity	[61]. 
In Ayurvedic medicine WS is used for a whole variety of disorders and 
pathologies. It has aphrodisiac, diuretic, narcotic and sedative properties, as 
the name implies. It is used as tonic-adaptogen and stimulant to increase 
vitality and longevity, characteristics that allowed WS earning the name 
“Indian ginseng” [63]. It demonstrated anti-Parkinson and anti-Alzheimer 
disease potential, and is considered a remedy for anxiety and depression [63]. 
It has anti-inflammatory, immune-modulating, anti-stress properties, and a 
well-documented antitumor potential, showing both antineoplastic and cancer 
chemopreventive activities [63]. More, it is able to sensitize tumor cells to 
radiation or chemotherapy, thus decreasing the most common side effects of 
conventional anticancer therapies when used in combination. An exhaustive 
body of literature supports these statements with many in vitro and animal 
studies [63]. 
Leaf, seed or root extracts have been tested to prove WS pleiotropic 
pharmacologic activities. For instance, aqueous leaf extract exhibited 
antiproliferative activity in osteogenic sarcoma and breast cancer cell lines [64], 
while the aqueous ethanolic root extract slowed down tumor growth and 
increased survival in albino mice affected by Dalton’s ascites leukemia [65]. As 
expected, WS antitumor mechanism of action is most likely multifactorial. It 
induces apoptosis, and shows both pro- and antioxidant activity (root extract) 
in different tumor models [66,  67]; it regulates cell cycle (methanolic root 
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extract) [68], inhibits angiogenesis (hydroalcoholic root extract) [69], and 
enhances the immune system in different animal models stimulating, among 
others, NK cells activity, macrophage count and chemotaxis (methanolic and 
hydroalcoholic root extracts) [62,  70,  71]. 
The lack of standardization in the preparation of the extract makes 
impossible a univocal characterization. However the pharmacological activity 
of the root is attributed to different alkaloids and steroidal lactones that in 
different amount are found in all WS extracts. The most characterizing 
elements are withanolides (family of steroids having an ergostane skeleton), 
withaferins (steroidal lactone) and sitoindosides (saponins) [63]. Witaferin A 
(WFA) is the most studied among all these compounds and demonstrated 
antineoplastic potential when used as a single agent. In vivo, it inhibited cell 
growth and increased surviving in prostate, medullary thyroid, soft tissue 
sarcoma, cervical, uvean melanoma, mesothelioma, pancreatic, and both 
human and mice breast tumor types [72]. As for WS extracts, WFA’s core 
mechanisms of action concern apoptosis induction, inhibition of angiogenesis 
and proteasome inhibition [72]. 
The promising overview here provided and, in particular, the renown 
anticancer and immunomodulating properties showed by different WS 
extracts made it a perfect candidate to evaluate its capability to induce ICD. 
1.2. Aim of the study 
During the first year of my PhD, my research aimed at a characterization 
of the pharmacotoxicological profile of a DMSO root extract of WS (WSDE) on 
acute T lymphocyte leukemia cells (Jurkat). I investigated WSDE antitumor 
potential in terms of cytotoxicity  – IC50  (inhibitory concentration causing cell 
toxicity by 50% following one cell-cycle exposure) – apoptosis and 
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proliferation. Then, I evaluated the capability of the same extract to induce ER 
and oxidative stress, in order to pave the way for the investigation of WSDE 
ability to induce ICD. To exploit the latter task, I assessed the ability of WSDE 
to mobilize the most significant DAMPs that are CLR, HSP70, HSP90 and ATP. 
The genotoxic potential was investigated in order to collect preliminary 
indications about the risk-benefit profile of WSDE. 
1.3. Results and Discussion 
Literature data show an enormous amount of different extracts 
obtained from the root of WS, all having interesting antitumor potential. 
We decided to test two extracts obtained with two different solvents: 
DMSO or a hydro-ethanolic solution (1:1). Both are polar solvents and both 
are able to dissolve either polar or non-polar substances, but in a different 
way since DMSO is an aprotic solvent, while the ethanol mixture is able to 
share hydrogen bonds. Thus, a very different biological activity was not 
expected. Cytotoxic activity of both extract has been tested on Jurkat cells 
and no significant differences emerged in their action (data not shown), 
implying that the active molecule extracted from the root of WS were 
almost the same using the two solvents. Taking into account the recognized 
easier dissolution of WFA in DMSO than in protic solvents, WSDE was 
selected for the study [73]. 
1.3.1. WE Contains Withaferin A (WFA), Whitanolide A (WDA), 
and Trace of Withanolide B (WDB) 
The most renowned markers of WS were detected and quantified 
through HPLC analysis. WSDE was enriched mostly in WFA (113.65 µg/mL) 
followed by WDA (39.42 µg/mL). WDB and Withanone were both in quantities 
under the limit of quantification (Table 1). This result is not surprising, since 
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WFA is the prevailing bioactive molecule found in different WS extracts [72,  
74,  75]. 
Since the aim of this research was the understanding of the antitumor 
activity of the extract in its entirety, from later on the more stringent activities 
of WSDE will be compared to the activity of the single phytomarker revealed 
through HPLC and to the combination of them at the same concentration 
found in the extract. This analysis would allow understanding whether these 
molecules all together exploit the biologic activity. 
Table 1. Quantification of WFA and WDA 
 
LOD: limit of detection, LOQ: limit of quantification, tr=trace 
 
1.3.2. WE Induces Apoptosis and Alters Cell-Cycle Residence 
WSDE induces a concentration-dependent reduction of cell viability in 
Jurkat cells. After 24 h of treatments with 1.60 or 3.20 mg/mL, the percentage of 
viable cells reached 64.4 and 16.6, respectively (Figure 1.1). The resulting IC50 
was 2.3 mg/mL. Concentrations close to the IC50 were chosen for the following 
experiments. Of note, the rationale of the assay used to measure cell viability 
was the distinction of the two populations (viable and dead) on the basis of 
cellular membrane permeability. Thus, an overestimation of the percentage of 
viable cells is unavoidable since it includes both viable and early apoptotic 
Compound Amount (µg/mL) LOD LOQ 
Amount (mg/g of 
dried extract) 
Recovery % 
WFA 113.65±2.84 6.54±0.11 19.81±0.63 5.68±0.14 96.85±1.98 
WDA 39.42±1.44 1.64±0.07 4.96±0.26 1.97±0.07 110.57±2.11 
withanolide B tr 2.03±0.34 6.36±0.65 / / 
withanone / 1.99±0.29 15.95±1.18 / / 
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cells, both characterized by membrane integrity. 
Figure 1.1 Percentage of viable Jurkat normalized to the untreated cells, after 24 h treatment with 
increasing concentration of the DMSO root extract of WSDE. 
Therefore, to discriminate whether the cytotoxic effect of WSDE on Jurkat 
cells was the result of a RCD, induction of apoptosis was investigated. After 6 
h of treatment at 0.40 and 0.80 mg/mL, WSDE increased the fraction of 
apoptotic cells compared to untreated cells of about 3.4 and 4.1 times, 
respectively. After 24 h treatment apoptosis was even more pronounced, and 
statistically significant starting from 0.40 mg/mL, where 33.1% of apoptotic 
events was observed versus 3.1% of untreated cells (Figure 1.2 A and 1.6 B). 
From 0.80 mg/mL treatment, the number of permeabilized cells (i.e. necrotic, 
necroptotic or late apoptotic cells) increased in a significant way (11.6% versus 
1.7% of untreated cells) (Figure 1.2 A and 1.6 B). At the highest tested 
concentration of WSDE (1.60 mg/mL), both apoptotic and “necrotic” events 
markedly increased, but the percentage of apoptotic cells was significantly 
higher than that of permeabilized cells (53.2% versus 28.2%, respectively) 
(Figure 1.2 A). Besides, we treated Jurkat with WFA, WDA or their association, 
at the same concentration found in the extract at 0.20, 0.40 and 0.80 mg/mL. An 













































cells, at all the concentrations tested (Figure 1.2 B). Furthermore, the 
proapoptotic effect of the association WFA plus WDA was very similar to that 
of WFA (Figure 1.2B), suggesting the inactivity of WDA at the tested 
concentrations. Nonetheless, the effect of WSDE was significantly higher than 
that observed for WFA or the association WFA plus WDA, which bolster the 
assumption that WSDE cytotoxic and proapoptotic activity stands on the 
synergistic activity on WFA and others, not yet identified, phytomarkers 
(Figure 2.2 C).  
Figure 1.2 Percentage of Percentage of viable (7AAD-/AnnV-), early apoptotic (7AAD-/AnnV+), and 
late apoptotic or secondary necrotic (7AAD+/AnnV+) after 24 h treatment of Jurkat cells with increasing 
concentrations of WSDE (A), WFA, WDA or WFA plus WDA (B). Fold increase in the percentage of 
apoptotic cells after treatment with different concentrations of WSDE, WFA, or WFA plus WDA (C). *, #, 







































































































7AAD+/AnnV+ (necrotic or late apoptotic)
7AAD-/AnnV+ (early apoptotic)
* * * * * *
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In the ensuing experiments, the cytostatic effect of WSDE has been 
investigated. Jurkat cells were treated for 24 h with increasing concentration of 
WSDE and provoked a blockage in G2/M phase that was significant starting 
from 0.10 mg/mL (39.6% versus 22.4% of untreated cells), complemented by a 
decrease in cells in phase G0/G1 (45.7% versus 63.0% of untreated cells) (Figure 
1.3). WSDE showed the same tendency up to 0.40 mg/mL, where we revealed 
an increase in cells in G2/M phase (30.3%) and a decrease in cells in G0/G1 
phase (50.1%), while at the highest concentrations tested, the cell-cycle 
distribution turns back to that of untreated cells (Figure 1.3). 
 
Figure 1.3 Cell-cycle distribution following 24 h treatment of Jurkat with increasing concentrations 
of WSDE. * p < 0.05; ** p < 0.01; *** p < 0.001 versus untreated cells.  
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with the characteristics of different withanolides and a methanolic crude leaf 
extract tested in different leukemia cell lines [76]. However, the mentioned 
methanolic leaf extract was much potent than WSDE in terms of IC50. This is 
not surprising, since the two extracts differ for the part of the plant used (root 
versus leaf) and more, the methanolic leaf extract was subjected to a sequential 
solvent extraction, which progressively concentrated the active components of 
WS leaves. Conversely, taken together, our results indicating that WSDE 
interferes with at least two of the hallmarks of cancer (resisting cell death and 
sustaining proliferative signaling) have to be highlighted. 
1.3.3. WSDE Increases Intracellular Ca2+ ([Ca2+]i) 
Numerous studies conveyed that calcium ionophores exhibit 
proapoptotic activity [77] and that a controlled intracellular [Ca2+] (i[Ca2+]) 
increase, prompted by milder insults, stimulate cell death through apoptosis 
[78]. Moreover, the release of [Ca2+] from the ER to the cytosol could be the 
consequence of ER stress and the resultant apoptosis an effect of it [78]. Since 
WSDE revealed marked proapoptotic ability, its faculty to modulate i[Ca2+] 
was explored. As well as for apoptosis, WSDE increased i[Ca2+] levels in a 
concentration-dependent way, starting from 6 h treatment and significantly at 
0.40 mg/mL [837.5 mean fluorescence intensity (MFI) versus 410.5 MFI of 
untreated cells] (Figure 1.4). After 24 h a significant increase in i[Ca2+] at all 
tested concentrations was registered and a fold increase of 3.7 times (1530 
versus 399.7 MFI of untreated cells) was obtained for the highest tested 
concentration (1.60 mg/mL) (Figure 1.4). Dead cells were analyzed separately 
as unique cluster. 
The demonstration that MSDE-treated Jurkat cells sustain a cytosolic 
[Ca2+] increase confirms the involvement of this cation in MSDE antileukemic 
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activity and gives a hint to move forward with the evaluation of the extract’s 
ability to trigger ER stress. 
 
 
Figure 1.4 Fraction of viable cells with increased i[Ca2+] following 6 and 24 h exposure to 
increasing concentrations of WSDE. * P < 0.05; ** P < 0.01;*** P < 0.001 versus untreated cells. 
 
1.3.4. WSDE Induces Oxidative and ER Stress 
In order to keep on unraveling WSDE mechanism of action and at the 
same time understand if it could be a suitable candidate for ICD studies, both 
oxidative and ER stress were investigated in WSDE-treated Jurkat. 
After 1, 3, 6, 18 and 24 h treatment with increasing concentrations of 
WSDE, ROS levels were recorded. The modulation of ROS started after 3 h of 
Jurkat incubation with the extract, but the highest levels were recorded after 6 
h treatments (Figure 2.5 A). At 6 h, 0.80 and 1.60 mg/mL of extract led to ROS 
levels similar or even higher than those promoted by a mildly toxic dose of 
H2O2 (0.1 mM for 15 minutes), used as positive control. After longer treatment, 
ROS escalation reached a plateau (data not shown). These data indicate that 





























results were obtained by Malik [79], who highlighted a significant ROS rise 
after 1 to 3 h of exposure to only WFA [80]. 
To understand the origin of ROS increased levels, Jurkat cells were 
treated with WSDE in combination with the non-selective ROS quencher N-
acetylcysteine (NAC), the copper chelating agent ortho-phenantroline or the 
inhibitor of mitochondrial electron transport at NADH-ubiquinone 
oxidoreductase rotenone. NAC prevented almost all ROS production since the 
ROS levels delivered through the co-treatment NAC-WSDE were comparable 
to those of untreated cells (Figure 1.5 B). Hydroxyl ions looked the main 
radical species involved in WSDE-mediated oxidative stress. Indeed, the co-
treatment of Jurkat cells with the extract plus ortho-phenantroline for 6 h 
prevented almost all ROS production (Figure 1.5 B) to the same extent of the 
effect produced by NAC in the same experimental conditions. Ortho-
phenantroline, in fact, is an inhibitor of Fenton reaction that is the main way 
through which H2O2 is transformed in hydroxyl ions. Of note, the results 
obtained with ortho-phenantroline confirm and avoid any doubt about the 
protection conferred by NAC to WSDA-treated cells, since this molecule was 
pointed as direct WFA quencher, implying that the protective role of NAC 
could be the consequence of the dismantle of WFA, instead of ROS demise. 
[72]. Conversely, rotenone didn’t exert any protective effect on WSDE-
mediated oxidative stress suggesting that mitochondrial complex I is not 
involved in this WSDA-mediated ROS production and that further studies will 








Figure 1.5 ROS levels in WSDE-treated cells. (A) Jurkat exposed to increasing concentrations of 
WSDE for 1, 3 or 6 h. Cells treated with H2O2 0.1 mM for 15 minutes represent the positive control (dotted 
line parallel to x-axis). (B) Cells were treated for 6 h with WSDE 0.80 mg/mL in the absence or presence of 
o-phenanthroline (o-Phe, 10 µM), rotenone (Rot, 2 µM) or N-acetylcysteine (NAC, 10 mM). Cells treated 
with H2O2 0.1 mM for 15 minutes represent the positive control. * P < 0.05, ** P < 0.01 and ***,°°° P < 0.001. 
 
Since ROSs look crucial in WSDE bioactivity and oxidative stress is one 
critical event promoting ICD, their role in WSDE-mediated apoptosis was 
evaluated. Jurkat cells have been treated with the extract plus NAC for 24 h. A 
significant decrease in the WSDE-induced apoptosis was observed (Figure 1.6 
A and B). The apoptotic events were significantly reduced from 33.1% after 
0.40 mg/mL of WSDE to 9.4% after WSDE plus NAC and from about 38.5%  
after 0.80 mg/mL of WSDE to 10.71% after WSDE plus NAC (Figure 1.6 A and 
B). These data clearly point out the involvement of oxidative stress in WSDE 
antileukemic potential. 
Beside ROS production, the other pivotal event eliciting ICD is ER stress. 
To evaluate WSDE capacity to induce ER stress we used an indirect method. 
We pre- and co-treated Jurkat cells with the ER stress inhibitor sodium 
tauroursodeoxycholate (TUDCA) [81]. Attenuation of ER stress by TUDCA 
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° significant vs Withania (WSDE)
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DHR = dihydrorodamine 123 
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protected Jurkat cells from WSDE-induced apoptosis (Figure 1.6 A and B). The 
apoptotic population was lessened in a lesser extent than NAC, but still 
significantly (from 33.1% 0.40 mg/mL of WSDE to 17.36% after WSDE plus 
TUDCA and from 38.5% after 0.80 mg/mL of WSDE to 23.28% after WSDE plus 
TUDCA) (Figure 1.6 A and B). Moreover, the combination of TUDCA and 
NAC significantly blunted WSDE-induced apoptosis showing how these two 
events, together, lead to apoptosis. These results are not surprising since WFA 
itself showed already the ability to trigger ER stress through eIF-2α (PERK 
main effector) activation and CHOP-mediated apoptosis in renal carcinoma 
Caki cells [82]. 
Taken together, these data demonstrated that oxidative and ER stress are 
the engine that drives WSDE-mediated apoptosis and represent a perfect 






Figure 1.6 Apoptotic events after 24 h of Jurkat treatment with WSDE in the absence and presence 
of NAC, TUDCA or NAC and TUDCA (A). * P < 0.05; *** P < 0.001; **** P < 0.0001 versus WSDE; 
representative dot plots of annexinV-PE/7AAD viability dye cell death assay of Jurkat cells 24 h after 
treatment with increasing concentration of WSDE, in the absence and presence of NAC, TUDCA or NAC 







































1.3.5. WSDE Induces DAMPs Trafficking 
To evaluate the ability of WSDE to induce ICD in vitro, the mobilization 
of the most representative and immunogenic DAMPs has been explored. The 
externalization of CLR, HSP70 and HSP90 on the outer leaf of the membrane 
and the ATP release were investigated after the treatment of Jurkat cells with 
WSDE.  
Although the analyzed DAMPs are usually mobilized during the early 
phases of apoptosis, none of them has been affected by WSDE after 6 h of 
treatment (data not shown). On the contrary, 24 h of incubation of Jurkat cells 
entailed the translocation on the extracellular membrane of CLR, (MFI of 8.39 
at 0.2 mg/mL and 8.72 at 0.4 mg/mL versus 6.83 of untreated cells) (Figure 1.8 
A), HSP70 0.2 mg/mL (57.92 MFI versus 42.17 of untreated cells) (Figure 1.8 B) 
and HSP90 0.2 mg/mL (151.09 MFI versus 58.45 of untreated cells) (Figure 1.8 
C). At 0.4 mg/mL, the expression of both HSP70 and HSP90 increased up to 
85.22 and 144.14, respectively (Figure 1.8 B and C, respectively). A significant 
increase in ATP levels has been recorded at both tested concentrations (2- and 
2.45-fold increase compared to untreated cells, respectively) (Figure 1.8 G). 
ICD induction was also investigated after Jurkat cell treatment with 
WDA and WFA, used at the concentration detected in the WSDE at 0.40 
mg/mL, alone or in combination for 24 h. No treatment caused any statistically 
significant DAMP’s trafficking (Figure 1.8 D-F), suggesting that the intrinsic 




Figure 1.8 Fluorescence hystograms of immunolabeled calreticulin (A), HSP70 (B) and HSP90 
(C) and modulation of the expression of calreticulin (D), HSP70 (E), HSP90 (F) and of ATP release (G) 
after treatment with WE, WFA, WDA or WFA plus WDA. Histograms are representatives of three 
independent experiments. * P < 0.05, and ** P < 0.01 versus untreated cells. 
 
1.3.6. WSDE Induces DNA Damage  
To explore more deeply the promising pharmacological profile of WSDE, 
we took the first step to assess its toxicological profile through the evaluation 
































































































































































































































concentration of WSDE for 6 h, and then histone H2A.x phosphorylation was 
analyzed. H2A.X phosphorylation at Ser 139 represents a sensitive marker for 
DNA single strand damage [83]. WSDE induced a dose-dependent increase in 
H2A.X phosphorylation, which was 8 times higher than untreated cells at the 
highest tested concentration (0.80 mg/mL). This increase was similar to the 
phosphorylation induced by etoposide 10 µM, used as positive control (Figure 
1.9). However, even if γ-H2A.x is an index of the ability of a compound to 
interact with DNA, the lesion recorded is pre-mutational, thus reparable per se. 
Further studies will be necessary to determine if the damage is repaired or 
fixed, estimating the actual mutagenic potential of WSDE. In contrast with our 
data, plenty of studies showed WFA chemopreventive activity. For instance, it 
was demonstrated its ability to provide protection against the 7,12-
dimethylbenz(a)anthracene-induced genotoxicity [84,  85]. The different 
genotoxic profile of WSDE and WFA could be explained by the so-called 
“matrix effects”. Indeed, it could happen that genotoxic studies on complex 
products of natural origin are performed on single phytochemicals rather than 
on the product in its complexity. The matrix effect can cause an incomplete 
release of a key constituent from the vegetal carrier or modulate its 
bioavailability. This means that the use of toxicity data concerning the pure 
phytochemical are unsuitable for assessing the risk derived from the use of the 





Figure 1.9 Relative expression of phosphorylated H2A.X (γ-H2A.X) induced by WSDE in Jurkat 
cells after 6 h of treatment. Etoposide (10 µM) was used as positive control. *** P < 0.001 versus untreated 
cells. 
1.4. Conclusions 
My first year of PhD ended with the characterization of the 
pharmacotoxicological profile of WSDE. I demonstrated the WSDE antitumor 
potential, which was exerted through a cytostatic activity and a ROS- and, to a 
lesser extent, ER-mediated apoptosis. I proved that, most likely, the actual 
reactive specie, to which the apoptotic effect is ascribed, is the hydroxyl 
radical, but I was not able to exactly localize oxidative stress inside the cell, 
whether data suggest an alternative region than mitochondria. Indeed, it 
would be easy to speculate that ROS could localize in the ER, since cytosolic 
[Ca2+] levels are increased after the treatment of Jurkat cells with WSDE and at 
the same time ER stress was registered. This conjecture would also agree with 













































cells. The most promising element is that all four DAMPs have been activated 
by WSDE treatment after 24 h of treatments and that, as explained above, the 
immunogenicity of a dying cell is directly proportional to the intensity of 
DAMPs’ emission. Of note, DAMPs mobilization has been registered for the 
sum of apoptotic and necrotic cells, without any distinction, since at the time 
of the execution of the experiments, the debate about the capability of necrotic 
cells to induce ICD was ongoing. Since in vivo vaccination is not possible in 
human models, translational studies on mouse models could help to estimate 
the real immunogenic properties of WSDE. However, these latter 
considerations do not change the very promising profile of the analyzed 
extract that still represents an interesting candidate for further ICD studies. 
To conclude, it’s worthy to remind that WS extracts and WS’s 
phytomarkers are currently available as dietary supplements to treat different 
disorders, including naturopathic care for infertility [87], anxiety [88], and 
osteoarthritis [89]. Hence, genotoxicity should be carefully taken into account 
for an accurate evaluation of the risk-benefit profile. It is important to 
emphasize once again that the H2A.X phosphorylation test used in our study 
detects premutational and thus reparable DNA lesions. For this reason, further 
experiments are needed to define the frank mutagenic effect of the lesions 
caused by WSDE and to directly relate the DNA damage to the potential 
mutagenic effect. 
1.5. Material And Methods 
1.5.1. Extract preparation 
WE roots were collected during summer (balsamic period) and 
authenticated by Dr. Paolo Scartezzini, Maharishi Ayurveda Product Ltd., 
Noida, India. The quality control was performed by Vedic Herbs s.r.l. 
(Caldiero, VR, Italy), which gifted us with a sample of root powder 
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(voucher #12/11). The extract was prepared by resuspending 10 g of Withania 
root powder with 100 mL of DMSO or ethanol. The suspension was vortexed 
for 15 minutes at room temperature and centrifuged at 4000 rpm for 5 minutes 
to discard any insoluble part. The experiments and the HPLC analysis were 
performed using the DMSO stock solution of 100 mg/mL.  
1.5.2. HPLC Analysis and Validation 
 WSDE extract was subjected to RP-HPLC-DAD analysis to identify and 
quantify the main phytomarkers. The reference compounds WFA, WDA,  
WDB, and withanone were purchased from Extrasynthese, Lyon, France. WFA 
and WDA were used as external standards to set up and calculate appropriate 
calibration curves. The analyses were performed using a Jasco modular HPLC 
(model PU 2089, Jasco Corporation) coupled to a diode array apparatus (MD 
2010 Plus) linked to an injection valve with a 20 µL sampler loop. The column 
used was a Kinetex XB-C18 (5 µm, 15 cmx0.46 cm) with a flow rate of 0.6 
mL/minutes. The analyses were performed at 25 °C with mobile phase and 
gradient chosen according to literature [90]. Following chromatogram 
recording, sample peaks were identified by comparing their ultraviolet (UV) 
spectra and retention time with those of the pure standards. Dedicated Jasco 
software (PDA version 1.5, Jasco Corporation, 2004) was used to calculate peak 
area by integration. The individual stock solutions of each phytomarkers were 
prepared in ethanol or acetonitrile. The calibration curves of the considered 
compounds were prepared within different range: 500–50 µg/mL for WFA, 
and 100–10 µg/mL for WDA. Each calibration solution was injected into HPLC 
in triplicate. The calibration graphs were obtained by the regression analysis of 
the peak area of the analytes versus the related concentrations. The analysis of 
the extract was performed under the same experimental conditions. The 
obtained calibration graphs allowed the determination of the concentration of 
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the phytomarkers inside the extract.   
LOD and LOQ were calculated following the approach based on the 
standard deviation of the response and the slope for WFA and WDA, on signal 
and noise ratio for WDB and withanone, as presented in the “Note for 
guidance on validation of analytical procedures: text and methodology”, 
European Medicine Agency ICH Topic Q2 (R1). The accuracy was reported as 
percent of recovery and was estimated by adding known amount of analyte in 
the studied sample. 
1.5.3. Cell Cultures and Treatments 
 Acute human T-lymphocytes leukemia cells (Jurkat) were provided 
from LGC standards. Cells were grown in suspension in Roswell Park 
Memorial Institute (RPMI) 1640 supplemented with 10% heat-inactivated 
bovine serum, 1% penicillin/streptomycin solution, and 1% L-glutamine 
solution (all obtained from Biochrom, Merck Millipore). Cells were incubated 
at 37 ̋C with 5% CO2. To maintain exponential growth, the cultures were 
diluted to never exceed the maximum suggested density of 3x106 cells/mL.  
 Jurkat cells at 1.5x106 cells/mL density were treated with increasing 
concentrations of WSDE (0.0–1.6 mg/mL) for 1, 3, 6 or 24 h, according to the 
experimental requirements, or with WFA, WDA or WFA plus WDA for 24 h. 
WFA and WDA were tested at the concentrations found in the WSDE extract 
at 0.2, 0.4 and 0.8 mg/mL: 0.23–0.92 µg/mL for WFA; 0.08–0.32 µg/mL for 
WDA. Etoposide 10 µM and hydrogen peroxide 0.1 mM were used as positive 
controls. For oxidative and ER stress-related experiments, Jurkat cells were 
pretreated with TUDCA 1 mM (Sigma Aldrich), NAC 4 mM or TUDCA and 




1.5.4. Analysis Of Cell Viability And Induction Of Apoptosis 
 To determine cell viability of Jurkat cells, Guava ViaCount Reagent 
(Merck Millipore) was used according to manufacturer’s instructions. Briefly, 
cells were appropriately diluted with the reagent containing 7-amino-
actinomycin D (7-AAD) and incubated at room temperature in the dark for 5 
minutes before detection with flow cytometer. Furthermore, to discriminate 
between necrotic and apoptotic events, Guava Nexin Reagent (Merck 
Millipore) was used. Through the use of 7-AAD and annexin V-phycoerythrin, 
the assay allows the discrimination of apoptotic and necrotic events. Cells 
were incubated with the reagent for 20 min at room temperature in the dark 
and then analyzed via flow cytometry. IC50 was calculated by interpolation 
from non-linear regression and log of concentration–response curve. 
Concentrations close to IC50 were used in the subsequent experiments.  
1.5.5. Cell-Cycle Analysis 
 After treatment with WSDE for 24 h, cells were fixed with 70% ice-cold 
ethanol and, after washing, suspended in 200 µL of Guava Cell Cycle Reagent 
(Merck Millipore), containing propidium iodide. At the end of incubation at 
room temperature for 30 minutes in the dark, samples were analyzed via flow 
cytometry.  
1.5.6. Measurement of [Ca2+]i 
 After WSDE treatment for 6 or 24 h, [Ca2+]i was analyzed by using Fura 
RedTM, AM (Thermo Fisher Scientific), according to manufacturer’s 
instructions. Briefly, after treatment, cells were incubated with the dye that 
freely permeates the cytoplasmic membrane but, once inside the cells, is 
hydrolyzed by the intracellular esterases and trapped into the cells. The 
fluorescence of this molecule is enhanced once it binds Ca2+. The use of the 
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lowest concentration of Fura Red is recommended. Following this 
experimental phase, the concentration of 1 µM was adopted. To detect 
intracellular calcium levels, Jurkat cells were incubated at 37 °C for 30 minutes 
in PBS without calcium and magnesium. This buffer condition allows 
detecting the intracellular calcium stores and excluding the secondary increase 
in [Ca2+]i due to Ca2+ entry [91]. Moreover, the removal of external Ca2+ reduces 
the non-specific fluctuations in [Ca2+]i normally observed during the first 20–30 
s of sample acquisition via flow cytometry. Results are expressed as MFI. 
1.5.7. Detection of ROS Levels 
ROS levels were determined after 1, 3, 6, 18 or 24 h of WSDE extract, 
alone or after a pretreatment with NAC 4 mM treatment by using the probe 
DHR 10 µM [92] or 2′,7′-dichlorofluorescin diacetate (DCFDA), which was 
added during the last 20 minutes of incubation. Hydrogen peroxide was used 
as positive control. After three washing in PBS, cellular fluorescence was 
imaged using a Leica DMLB/DFC300F fluorescence microscope (Leica 
Microsystems) equipped with an Olympus ColorviewIIIu CCD camera 
(Polyphoto). Fluorescence images (100 cells per sample from randomly selected 
fields) were digitally acquired and processed for fluorescence determination at 
the single cell level on a personal computer using the public domain program, 
Image J. Mean fluorescence values were determined by averaging the 
fluorescence of at least 100 cells/treatment condition/experiment.  
1.5.8. Analysis of Calreticulin, HSP70 And HSP90 Expression, and 
ATP Release 
After 6 or 24 h of treatment, cells were washed and incubated with 
phycoerythrin-labeled calreticulin antibody (1:100, Abcam). To analyze HSP70 
and HSP90 expression, cells were incubated with an anti-HSP70 or anti-HSP90 
	
49	
antibody (1:100, Abcam, for both antibodies) and, after washing, incubated 
with fluorescein isothyocianate-labeled secondary antibody (1:100, Sigma, 
Merck Millipore) MFI was detected via flow cytometry and compared to the 
untreated cells.  
 The kit ATPLiteTM 1step (Perkin Elmer, Waltham, MA, USA) was used 
for the detection of ATP extracellular concentration. Jurkat cells were seeded 
and treated with WSDE in Hank's Balanced Salt Solution (HBSS) or complete 
medium for 6 and 24 h, respectively. At the end of incubation, supernatants 
were collected and treated with 100 µL of ATPLite 1step reagent containing 
luciferase and D-luciferin. After shaking for 2 minutes at 700 rpm using the 
orbital microplate shaker 711/+ (Asal srl), luminescence of the samples was 
measured in a 96-well black plate using the microplate reader Victor X3 
(Perkin Elmer).  
1.5.9. DNA Damage Analysis 
 Phosphorylation of histone γ-H2A.X was used as marker of WSDE 
genotoxic potential. After 6 h of treatment with WSDE, cells were fixed, 
permeabilized and incubated for 30 minutes in the dark at room temperature 
with an anti- γ-H2A.X-Alexa Fluor® antibody (Merck Millipore). Etoposide 10 
µM was used as positive control. Samples were analyzed via flow cytometry.  
1.5.10. Flow Cytometry 
 EasyCyte 5HT (Merck Millipore) were used to perform all flow 
cytometric analyses, with the exception of the measurements of [Ca2+]i 
performed by using a FACSCanto II (BD Bioscience, Franklin Lakes, NJ, USA). 




1.5.11. Statistical Analysis 
 All results are expressed as mean ± SEM of at least three independent 
experiments. Differences between treatments were assessed by t test or one-
way ANOVA and Dunnet or Bonferroni was used as post-tests. All statistical 
analyses were performed using GraphPad InStat 5.0 or 6.0 version (GraphPad 




CHAPTER 2. MG28 
2.1. Introduction 
Isothiocyanates (ITCs) are very reactive sulfur-containing compounds 
(Figure 2.1). This ITC chemical moiety is stabilized by resonance in a way that 
sulfur and nitrogen attract all the electrons. In this way the electrophilic central 
carbon is the perfect target for nucleophilic compounds, such as thiols, amino 
groups, and hydroxide ions [93], all chemical groups eventually occurring in 
many proteins or intracellular structures. 
 
 
Figure 2.1 Chemical structure of an isothiocyanate 
 
Brassicaceae (Cruciferae) family, which includes Brussels sprouts, broccoli, 
cauliflowers or kale cabbages, is the richest source of ITCs, in nature. ITCs are 
molecules stored in the plants in the form of precursors, the glucosinolates. 
Myrosinases catalyze the hydrolysis of glucosinolates into ITCs. These 
enzymes are kept close to glucosinolates, but in separated compartments and 
allow the conversion of glucosinolates only when plant’s tissues are ruptured 
and the two entities come into contact, as after insect attacks, chewing, 
chopping or cooking preparation. If this is not enough, in mammals, 
myrosinases springing from the gastrointestinal tract bacteria complete the 
conversion [93]. 
Many studies related the food intake of brassicaceae, against different 
types of cancer [94].  These effects are imputable to their content of ITCs. Some 




benzyl isothiocyanate (BITC), are highly efficient chemopreventive and 
antitumor agents [95]. ITCs’ antitumor potential relies on their ability to induce 
apoptosis, cell-cycle arrest, angiogenesis and histone deacetylation inhibition, 
and modulating many other pathways [93]. Moreover, oxidative stress is often 
the key of their mechanism of action. For instance, PEITC provoked apoptosis 
of myeloblastic (ML-1) and promyelocyte leukemia (HL-60) cells through 
glutathione (GSH) depletion and the consequent increase of oxidative stress, 
while SFN caused ROS-mediated apoptosis in U937 promonocytic leukemia 
cells [96], glioblastoma cells, [97], and in PC-3 and DU145 human prostate 
cancer cells	[98]. 
Despite the promising characteristics of ITCs, their aptitude to exert ICD 
has never been investigated.  
Bearing in mind 1) that the two crucial events that trigger ICD are 
oxidative and ER stress, and 2) the interesting antitumor potential and 
reactivity of the chemical ITCs moiety, and 3) that type II ICD inducers are 
able to exert a more efficient immunogenic response than type I [48], we 
designed an ITC derivative which could reach directly the ER and trigger ROS-
mediated apoptosis together with ER stress. Dott. Andrea Milelli from the 
University of Bologna, Department for Life Quality Studies, synthesized and 
provided us with MG28. MG28 is a molecule composed by a renowned ER 
carrier [99] bonded to the ITC moiety through an aliphatic chain (Figure 2.2). 









2.2. Aim of the study 
During the second year of PhD, my research aimed at drawing the 
pharmacological profile of MG28 with a particular focus on those 
characteristics that make it a candidate for ICD studies. The project took place 
in two phases. During the first phase, preliminary studies were carried out to 
assess the antitumor potential of MG28 in terms of cytotoxicity, apoptosis 
studies and oxidative profile on a human cell line of leukemia (Jurkat), while 
in the second phase the results obtained has been translated on a murine cell 
line of colon cancer (CT26) in order to pave the way for potential in vivo 
studies in syngeneic mice. The latter part of my research was held at the Cell 
Research and Therapy Laboratory of Cellular Medicine, Department of 
Cellular and Molecular Medicine of the Catholic University of Leuven, under 
the supervision of Prof. Agostinis and Dr. Abhishek Garg. 
2.3. Results and Discussion 
2.3.1. MG28 has Intrinsic Fluorescence 
In order to draft MG28 profile, its fluorescence spectrum was recorded 
(Figure 2.3). At any wavelength it was excited, the maximum emission was 
reached at 518 nm. However, MG28 emission covers a broad range of 
wavelengths, which prominently limited the use of all those techniques that 





Figure 2.3 Excitation (green line) and emission (blue line) spectrum of an MG28 solution 1.33 µM in 
methanol prepared from a stock solution 4.00 mM in DMSO. 
2.3.2. MG28 Reaches the ER 
To make sure that MG28 reached the ER, localization studies were made. 
Since the thin layer of cytoplasm of Jurkat cells made the subcellular 
localization of MG28 problematic, this model was replaced using the same cell 
line utilized by Hakamata et al. in the paper where the ER carrier per se was 
described: HeLa cells [99]. HeLa cells were transfected with the red fluorescent 
protein (RFP) version of the ER resident CLR and treated with a low 
concentration of MG28. After 6 h of treatment, cells were fixed and analyzed 
(Figure 2.4). The right image of Figure 3.4 shows the merged version of the 
green fluorescence of MG28 and the red one of RFP and confirms the 
localization at ER. However the green fluorescence of MG28 is diffused within 
the cell, suggesting the non-specific localization of the studied ITC derivative. 
The high reactivity of the ITC moiety could be responsible for the 
dissemination of the molecule. In fact, the amino groups or thiols of proteins 
and molecules inside the cell could attract the electrophilic carbon of the ITC, 




Figure 2.4 Microscopic analysis of HeLa cells transfected with red fluorescent protein (RFP)-
calreticulin (ER localization) and treated with subtoxic concentration of MG28. Representative co-
localization experiment: the fluorescence images for MG28 (left) and RFP (middle) were taken and 
merged (right). The merged image shows MG28 localization at ER in a non-specific way. 
 
2.3.3. MG28 is Cytotoxic for Both Jurkat and CT26 cell lines 
After 24 h treatment, MG28 induced a concentration-dependent decrease 
in cell viability in both human and murine cell lines. On Jurkat cells, MG28 
cytotoxic activity was significant starting from 2 µM (86.9% of viable cell). At 4 
µM the cell viability was 65.5% and reached 13.6% at 16 µM (Figure 2.5 A). The 
IC50 obtained from these results was 5.85 µM. The IC50 obtained testing MG28 
on CT26 cells was 7.80 µM. In the latter case the effect of MG28 treatments 
started to be significant at 5.0 µM concentration (16,71% of dead cells). The 
percentage of dead cells was 40.68 and 31.30 at 7.5 and 10 µM, respectively 
(Figure 2.5 B). Since the two cell lines differ from tumor type and host, the 
slight difference between the two IC50 is coherent and acceptable. 
Concentrations around the respective IC50 were chosen for the further 
experiments. 
Additionally, to exclude that the cytotoxicity of MG28 was driven by the 
ER carrier instead of the ITC moiety, Jurkat cells were treated with the only 
carrier, MG27 (Figure 2.6 A). The carrier didn’t exert any significant decrease 
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in cell viability until 32 µM treatment (Figure 2.6 B), highlighting the crucial 
role of the ITC in the MG28 antitumor activity. 
 
Figure 2.5 Percentage of viable Jurkat (A) or CT26 (B) cells after 24 h treatment with increasing 
concentration of MG28. *P < 0.05; ****P < 0.0001.  
 
Figure 2.6 MG27 chemical structure (A); Percentage of viable Jurkat cells after 24 h treatment with 
increasing concentration of MG27 (B). **P < 0.01. 
 









































































2.3.4. MG28 Induces Apoptosis Through both Intrinsic and 
Extrinsic Pathway in Jurkat Cells 
To dissect the mechanism of action of MG28, apoptosis studies have been 
performed. Twenty-four h of treatments at 6 and 8 µM resulted in 13.81 and 
56.33% of apoptotic Jurkat cells, respectively (Figure 2.7 A). Moreover, MG28 6 
µM stimulated caspase-3 activity 6.89 times more than untreated cells (Figura 
2.7 B), confirming the involvement of apoptosis in MG28 antitumor potential. 
At this point we analyzed which apoptotic pathway was involved in the 
proapoptotic potential of MG28. Cell-surface death receptors activate the 
extrinsic pathway of apoptosis. Upon activation they cluster and form the 
death-inducing-signaling complex that in turn provokes the cleavage (i.e 
activation) of procaspases 8, 10 or both, which stimulate the effector caspase 3. 
The intrinsic pathway depends on the mitochondria and involves the 
mitochondria outer membrane permeabilization (MOMP). MOMP provokes 
the release of proteins into the cytoplasm. Among these proteins, cytochrome c 
is crucial to assemble the apoptosome, the structure that in turn activates 
caspase 9. Then, caspase 9 triggers the effector caspases 3 and 7 that lead to 
apoptosis [100]. Therefore, MG28’s ability to modulate caspase 8 activity and 
alter mitochondrial potential was evaluated. At 6 µM, MG28 increased 2.22 
times the activity of caspase 8 compared to untreated cells (Figure 2.7 C) and  
decreased the mitochondrial potential of 32.96% of cells versus 5.32% of the 
untreated cells (Figure 2.7 D). Thus, MG28 triggers both apoptotic pathways. 
This evidence is very interesting since, very often, chemotherapeutic drugs 
elicit apoptosis through the only intrinsic pathway [101]. Thus, on one hand 
the double activation could bring to a more efficient apoptotic induction and 
on the other hand it could restore sensitivity in resistant tumors, in the case of 






Figure 2.7 Percentage of apoptotic Jurkat cells after 24 h treatment with increasing concentration of 
MG28. Apoptosis was assessed by Fast Halo assay (A) Caspase 3 (B) and Caspase 8 (C) activity was 
evaluated and compared to untreated cells after Jurkat treatment with increasing concentration of MG28 
through colorimetric assay. Fraction of Jurkat cells with decreased mitochondrial potential after MG28 
treatment assayed through flow cytometry analysis after incubation with the fluorescsnt dye cyanine dye 
DiIC1(5) (D). ** P < 0.01;  *** P < 0.001; **** P < 0.0001. 
2.3.5. MG28 Does not Trigger Apoptosis nor ER Stress in CT26 
Mixed results were obtained for the apoptotic potential of MG28 on CT26 
cells. To first understand if this form of RCD was involved in MG28 
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mechanism of action, we decided to block the activity of the apoptosis 
mediators, caspases. Thus, we pretreated and co-incubated MG28-treated 
CT26 cells with the pan caspase inhibitor Zvad-fmk. After 24 h of 7.5 and 15 
µM, the blockage of apoptosis resulted in an increase in cell viability of 1.69 
and 4.19 times, respectively, compared to only MG28-treated cells (data not 
shown). However, the protective effect of Zvad-fmk didn’t completely restore 
cell viability, implying a secondary mechanism of action involved in MG28 
modus operandi. To confirm these data, apoptosis was directly assessed through 
flow cytometry analysis, operating the Annexin V/dead cells assay. Briefly, one 
characteristic event of early apoptotic cells is the early translocation of 
phosphatidylserine (PS) from the inner to the outer side of the plasma 
membrane and its exposure to the external cellular environment. In vivo, PS 
acts as a marker of recognition for macrophages, while in vitro represents a 
useful marker of apoptosis.  Annexin V is a Ca2+-dependent phospholipid-
binding protein with high affinity for PS. Annexin V labeled with a 
fluorophore identifies apoptotic cells by binding to PS exposed on the outer 
leaflet. Then, adding a viability dye, which discriminates viable and dead cells 
on the basis of membrane permeability, makes the discrimination among four 
different cellular populations: viable (Annexin V negative/viability dye 
negative), early apoptotic (Annexin V positive/viability dye negative), late 
apoptotic, secondary necrotic or necroptotic (Annexin V positive/viability dye 
positive) or primary necrotic (Annexin V negative/viability dye positive) cells	
[102-104]. Flow cytometry analysis showed that after 24 h MG28 induced 
necrosis (Figure 2.8 A), with no early apoptosis detected. In particular, data 
suggested that primary necrosis is the main pathway through which MG28 
exerts cytotoxicity.  
Since these results were in contrast with previous data, we expolred if, at 
least in part, apoptosis was involved in MG28 antitumor potential on CT26. 
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Thus, during the following steps MG28’s ability to induce caspase 3 and its 
substrate poli ADP-riboso polimerase (PARP) cleavage was assessed [105]. A 
slight and non-significant increase of cleaved PARP was recorded after 24 h 
treatment of CT26 (Figure 2.8 B), while no caspase 3 activation was detected 
(Figure 2.8 B). 
These data, taken together, suggest that MG28 antitumor potential on 
CT26 does not rely on apoptosis. The protective effect of caspases inhibition, 
plus the slight activation of PARP can together indicate that apoptosis is one 
event eventually implied in MG28 activity, whereas its entity is not enough to 
be measured by the annexin V assay, nor to provoke a detectable amount of 
cleaved caspase 3. 
 
Figure 2.8 Representative dot plots of annexinV-PE-Cy7/Sytox Red Dead Cell Stain cell death assay 
of CT26 cells 24 h after treatment with MG28 8 µM (A). Representative blots of at least three independent 
experiments analysis for PARP and caspase 3 (total and cleaved) protein levels in MG28-treated CT26 









































Since the aim of the study was to assess MG28’s ability to trigger ICD and 
ICD doesn’t rely exclusively on apoptosis, its ability to trigger Perk-mediated 
ER stress was investigated. A PERK knockout CT26 cell line was used. We 
tested MG28 cytotoxic activity on the PERK-knockout cell line and compared 
the effects obtained on the wild type cells. No difference was recorded (data 
not shown), suggesting that the antitumor potential of MG28 on the murine 
cell line does not involve PERK-mediated ER stress. 
The very moderate activity of MG28 on CT26 cells provides input into the 
study of MG28 on Jurkat cells. 
Furthermore, the different antitumor potential of M28 on Jurkat and 
CT26 cells cannot be considered completely surprising. More than once, drugs, 
which have proven to be effective on human models, were not active when 
tested on mice, and vice versa [106]. The differences between human or animal 
activity to a same drug can be attributed to the different evolutionary and 
developmental intrinsic biology that in turn translates, for instance, into 
dissimilarities in gene regulation and expression or epigenetics discrepancies. 
Moreover, the two cellular models represent two different types of neoplasms 
(leukemia and colon cancer), and specific cancer-related mutations can 
significantly alter the response to drugs [107].  
2.3.6. Oxidative Profile of MG28 on Jurkat Cells 
The study progressed with the evaluation of MG28’s ability to prompt 
oxidative stress in Jurkat cells. Since emission spectra of DCFDA or DHR, the 
two most common probes used to assess intracellular ROS levels, overlap with 
the emission of MG28, oxidative stress was evaluated through an indirect way. 
Based on the major role of glutathione (GSH) as crucial cellular antioxidant, its 
content after MG28 treatments was recorded. After 1 and 3 h, all tested 
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concentrations induced a decrease in GSH levels compared to untreated cells. 
However, following the initial drop, GSH content increased in a time-
dependent manner (Figure 2.9 A). After 6 h at 2 µM and 24 h for all the other 
tested concentrations, GSH content exceeded the one recorded for untreated 
cells. The initial lower intracellular levels of GSH could be the consequence of 
increased ROS levels or the direct interaction between the ITC moiety and the 
thiol group of GSH, which in turn would be depleted. Indeed, the conjugation 
with GSH is the main mechanism through which ITCs are removed from cells 
[108]. For example, in HL60 and ML1 leukemia cells, PEITC formed GSH S-(N-
phenethylthiocarbamoyl)-GSH that was then exported from cells [109]. Thus, 
to understand the role of GSH in MG28 cytotoxicity and how the low GSH 
levels recorded after MG28 treatment are linked to ROS, we evaluated MG28 
cytotoxic potential on Jurkat cells after pretreatments with the antioxidant and 
GSH precursor NAC, or with the GSH synthesis inhibitor buthionine 
sulfoximine (BSO). Of note, we avoided the simultaneous treatment of Jurkat 
cell with NAC and MG28 to prevent the direct interaction and subsequent 
quenching of MG28. Interestingly, NAC pretreatment didn’t affect MG28 
activity, while it recovered Jurkat viability when treated with H2O2, used as 
positive control (data not shown). On the contrary, BSO pretreatment 
provoked a more cytotoxic effect on Jurkat cells than MG28 alone (Figure 2.9 
B). Taken together, these results demonstrated that the antitumor potential of 
MG28 does not rely on oxidative stress, since the ROS quencher NAC didn’t 
exert any protection, but demonstrated the pivotal role of GSH. Indeed, 
depletion of GSH significantly entails MG28 cytotoxicity. Taken into 
consideration both the effect of NAC and BSO, the most probable hypothesis is 
that GSH directly binds MG28 in order to favor its externalization. This would 
explain the initial decrease in free GSH after MG28 treatment and the higher 
toxicity when GSH is absent. Moreover, the subsequent increase in GSH 
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content could be the effect of the stimulation of the nuclear factor (erythroid-
derived-2)-like 2 (Nrf2). Nrf2 is a transcription factor playing a major role in 
controlling oxidative status through the modulation of the expression of many 
antioxidant proteins, such as GSH. Indeed, the same GSH trend induced by 
MG28 was observed in SFN-treated mouse embryonic fibroblasts (MEFs). 
There, following a GSH initial acute depletion (4 h of exposure to SFN), after 
18 h GSH increased in a Nrf2-dependent way	[110]. 
 
Figure 2.9 GSH content expressed as percentage compared to untreated cells, after 1, 3, 6 or 24 h 
treatments (A); percentage of viable cells of MG28-treated Jurkat cells alone or after 24 h pretreatment 
with NAC 5mM or BSO 0.2 mM (B). ** P < 0.01; *** P < 0.001. 
On the whole, our results taken together draw an interesting picture of 
the antileukemic activity of MG28. However the lack of the ability to trigger 
oxidative stress does not allow to keep on investigating its ICD potential. 
2.4. Conclusions 
MG28 is an ITC derivative constituted by an ER carrier linked to the 
active side through an aliphatic chain. It was synthesized ad hoc with the 
precise aim to bring an active chemical moiety to the ER, and to concurrently 
elicit oxidative and ER stress. In this way a type II of ICD inducer would have 















































still the most reliant and effective immunogenic anticancer therapy promoter.  
Firstly we ensured that MG28 would reach the ER, and thanks to its 
green intrinsic fluorescence it was not hard to find it out. It does reach the ER, 
but its localization is not selective and it clearly diffuses all over the cell. 
We tested MG28 antitumor activity on two different cell lines, a human 
leukemia cell line (Jurkat) and a murine colon cancer cell line (CT26). The latter 
model was chosen to pave the way to in vivo syngeneic studies. However, in 
this cell line MG28 did not exert the expected effects. It induced a cytotoxic 
activity attributable more to necrosis than to apoptosis and did not produce 
PERK-mediated ER stress. Thus, the research focused on the leukemia model. 
In this case, the pharmacologic profile of MG28 was very promising. It induced 
apoptosis at µM range concentrations, triggering both intrinsic and extrinsic 
pathways, thus doubling the probability of success in apoptosis-resistant 
cancer cells. However, the oxidative profile of MG28 did not deserved further 
studies to assess its ability to trigger ICD. Indeed, its mechanism of action did 
not rely on ROS production, since the pretreatment with the ROS quencher 
NAC did not affect its antitumor potential. On the contrary, our data 
suggested that long-term treatments increase GSH intracellular contents, 
probably through Nrf2 activation. 
Even if we expected different results, the inability of MG28 to trigger 
oxidative stress and its conjugation and quenching with the cysteine 
sulfhydryl group of GSH is a possibility. The chemopreventive properties of 
ITCs actually reside on the induction of phase II enzymes [111]. For example 
SFN, probably the most studied ITC, has the dualistic nature of 
chemopreventive promoter, thus showing antioxidant properties, and 
antitumor agent using ROS increased level as the engine which drives its 
activity [95], depending on the dose. 
In conclusion, the antileukemic profile of MG28 is very interesting and 
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should be deeply unravel. However it does not endow the characteristics 
needed to trigger ICD and for this reason this project was suspended.  
2.5. Material and Methods 
2.5.1. Synthetic Compounds 
MG27 and MG28 were provided by Dr. Andrea Milelli from the 
University of Bologna, Department for Life Quality Studies. MG28 is 
composed by an active ITC moiety linked to a renowned ER carrier through an 
aliphatic chain (Figure 2.2). MG27 represents the non-active part of MG28. 
2.5.2. Cell Cultures and Treatments 
 Jurkat, CT26 and PERK-/- CT26 were cultured in RPMI 1640 (Sigma), 
while HeLa in Eagle's Minimum Essential Medium (EMEM). All media were 
completed with 1 mmol/L glutamine, penicillin–streptomycin (Sigma) and 10% 
FBS at 37 °C under 5% CO2. Jurkat cells were obtained from the ATCC and 
always seeded at 1.5x106 cells/mL of complete medium. They were treated 
with MG27 (0 – 32 µM) or MG28 (0 – 32 µM) for the indicated time. With a 
density of 0.010x106/0.33 cm2 of well surface, HeLa, CT26 or CT26 PERK-/- were 
seeded and treated with MG28 (0 – 40 µM) for the indicated time. 
2.5.3. Localization Study 
HeLa cells were transfected with CellLight® ER-RFP (Thermo Fisher 
Scientific) following manufacture’s instruction. Then, cells were treated with 
MG28 1 µM for 6 h, fixed with paraformaldehyde 4% for 10 minutes, washed 
and observed by an Olympus FV1000 fluorescent microscope. The analysis 
was performed through the Image J software. 
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2.5.4. Analysis of Cell Viability 
Cell viability was assessed after 24 h treatments. For Jurkat cells, analysis of 
cell death was performed with Trypan blue Exclusion Assay as described in 
Buytaert et al [112]. To assess MG28 oxidative profile, cells were pretreated for 
24 h with NAC (Sigma Aldrich) 5 mM (GSH 150% vs Control) or BSO (Sigma 
Aldrich) 0.2 mM (GSH 20% versus Control). 
 Alternatively, to determine the amount of CT26 and PERK-/- CT26 cell 
death, intracellular alkaline esterase activity was measured through the 4-
Methylumbelliferyl heptanoate (MUH) assay (SIGMA), according to 
manufacturer’s instructions. Briefly, after 24 h treatment in 96-well plate, colon 
cancer cells were incubated with 0.01 mg/mL MUH in PBS for 20 minutes at 
37°C. The fluorescence was measured with Flex Station (Molecular Devices) 
with excitation 355 nm, emission 460 nm and cut off value 455 nm. For 
caspases inhibition, cancer cells were preincubated for 2 h with zVAD-fmk 
(Bachem, 50 µM). Incubation with zVAD-fmk continued throughout the 
treatments. 
2.5.5. Analysis of Apoptosis 
To allow the detection of apoptosis in Jurkat cells, DNA double strand breaks 
(DSBs) were assessed through the Fast Halo Assay (FHA), carried out at non-
denaturing pH conditions. Briefly, after the 24 h treatments, Jurkat cells were 
resuspended at 4.0×104/mL in ice-cold PBS containing 5 mM EDTA: 25 µL of 
this cell suspension was diluted with an equal volume of 1% low melting 
agarose in PBS and immediately sandwiched between an agarose-coated slide 
and a coverslip. After complete gelling on ice, the coverslips were removed 
and the slides were immersed in a lysis solution (0.15 M NaOH, 0.1 M 
NaH2PO4, 1 mM EDTA, Triton ×100 1% v/v, pH 10.1) for 10 minutes, incubated 
for further 15 minutes in PBS (pH 7.4) containing 0.1 mg/mL RNase (bovine 
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pancreas Type 1A); ethidium bromide was directly added to this solution 
during the last 5 minutes of incubation. The slides were then washed and 
destained for 5 minutes in distilled water and analyzed The ethidium bromide-
labelled DNA was visualized using a Leica DMLB/DFC300F fluorescence 
microscope (Leica Microsystems) equipped with an Olympus Colorview IIIU 
CCD camera (Olympus Italia Srl) and the resulting images were digitally 
recorded on a PC and processed with an image analysis software (Scion Image, 
Scion Corporation). The amount of fragmented DNA diffusing out of the 
nuclear cage, i.e. the extent of strand scission, was quantified by calculating the 
nuclear diffusion factor (NSF), which represents the ratio between the total 
area of the halo and nucleus and that of the nucleus.  
 For CT26, apoptosis was assessed using the annexinV-PE-Cy7 
(eBioscience)/SYTOX® Red Dead Cell Stain (Invitrogen). After 24 h treatments, 
cells were detached with Tryple (Thermo Fisher Scientific) and collected 
together with the respective treated medium, in order to recover also detached 
cells. Each sample was washed with PBS and with Annexin V - binding buffer 
(10 mM Hepes pH 7.4 , 140 mM NaCl), followed by resuspension in 
AnnexinV-PE-Cy7 (1/20 dilution in staining buffer) and Sytox red (1:1000 
diluition in Annexin V - binding buffer). After 15 minutes incubation at room 
temperature, cell suspension was diluted with Annexin V-binding buffer and 
analysed on Attune Flow Cytometer (Life Technologies).  
2.5.6. Caspases 3 and 8 Activity 
Proteolytic activities of caspases 3, and 8 enzymes in Jurkat cells were 
measured using colorimetric protease assays (Invitrogen Molecular Probes) 
according to the manufacturer’s instructions. At the end of the 24 h incubation, 
cells were subjected to two freeze-thaw cycles, followed by centrifugation at 
15,000 ×g for 15 minutes. The protein content in the supernatants was 
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determined by the BCA (Pierce™ BCA Protein Assay Kit) protein assay. A 
total of 50 µg of protein was incubated with 5 µl of DEVD-pNA or IETD- pNA 
in 50 µl of reaction buffer at 37 °C for 2 h in the dark. The optical density of the 
reaction mixture was then quantitated at a wavelength of 405 nm using thr 
microplate reader Victor X3 (Perkin Elmer). 
2.5.7. Mitochondrial Potential Assay 
Mitochondrial membrane potential (Δψm) was measured with the 
MitoProbe™ 1,1′,3,3,3′,3′-hexamethylindodicarbocyanine iodide (DiIC1(5)) 
assay kit (Molecular Probes) as instructed by the manufacturer. Briefly, Jurkat 
were collected, washed once with PBS, and labeled with 50 nM DiIC1(5) 
(excitation/emission, 638/658 nm) at 37 °C in the dark for 30 minutes. After 
been washed once in PBS, all samples were analyzed by Guava EasyCyte 5HT 
(Merck Millipore) flow cytometer. Carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP) was used as positive control. 
2.5.8. Western Blot 
Protein extraction and immunoblot analysis were performed using a 
modified Laemmli sample buffer (125 mM Tris-HCl, pH 6.8 buffer 
containing 2% SDS and 20% glycerol) in the presence of protease and 
phosphatase inhibitors (Roche). Lysates were separated by SDS-PAGE under 
reducing conditions, transferred to a nitrocellulose or PVDF membrane, and 
analyzed by immunoblotting. Primary antibodies used were anti-PARP 
(Biomol Research Labs), anti-caspase-3 (Santa Cruz) or anti-claeaved-caspases 
3 (Santa Cruz Biotechnology) and anti-actin (SIGMA). Appropriate secondary 
antibodies were from Thermo Fisher Scientific. Amersham ECL HRP-linked 
sheep anti-mouse immunoglobulin G (IgG) and donkey anti-rabbit IgG 
antibodies were from GE Healthcare Life Sciences. After incubation with the 
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appropriate secondary antibodies conjugated to horseradish peroxidase, 
blots were revealed using ECL western blotting substrate (Pierce), or 
Western Lightning plus-ECL (PerkinElmer). 
2.5.9. GSH Quantification 
After incubation time, cells were washed, collected and centrifuged at 
1,000xg for 5 minutes and washed in PBS. The pellet was lysed in 60 µL of 
CelLytic M reagent (Sigma Aldrich), kept on ice and vortex for 15 minutes. 
Cellular debris were removed by centrifugation at 15,000xg for 15 minutes at 
4°C. The protein content was quantified according to Bradford using bovine 
serum albumin as a standard	[113]. Protein precipitation was obtained adding 
25 µl of trichloroacetic acid 10% to 60 µL of supernatant. The solution was 
vortexed, kept on ice for 5 minutes and centrifuged at 14,000 rpm for 5 minutes 
at 4°C. The oxidation of GSH by the sulfhydryl reagent 5,5'-dithio-bis(2-
nitrobenzoic acid) (DTNB) in Tris-HCl buffer (Tris-HCl 0.4 M, EDTA 20 mM, 
pH 8.9) led to formation of the yellow derivative 5'-thio-2-nitrobenzoic acid 
(TNB), that was measured at 412 nm [114]. 
2.5.10. Statistical Analysis 
 All results are expressed as mean ± SEM of at least three independent 
experiments. Differences between treatments were assessed by t test or one-
way ANOVA and Dunnet or Bonferroni was used as post-tests. All statistical 
analyses were performed using GraphPad InStat 6.0 version (GraphPad 
Prism). P < 0.05 was considered significant.  
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CHAPTER 3. Hemidesmus indicus 
3.1. Introduction 
 
Hemidesmus indicus (HI) is a common weed found all over India. It 
naturally occurs in uncultivated soils or open scrub jungles and in all 
mesophytic habitat and semi dry regions of Pakistan, Sri Lanka, Moluccas, 
Bangladesh and Iran [115]. 
HI is an undershrub characterized by several wiry-thin branches with a 
purple-brownish cortex. Stems and branches twine anticlockwise and are 
elongate and narrow. The petiolate leaves are apiculate, obtuse or acute, and 
arrange in an opposite organization. They are dark-green on the upper leaf 
and paler, and eventually pubescent, on the other side. Flowers can vary from 
yellow to purple, depending on the specie. Five lobes form the calyx and the 
gamopetalous corolla is about twice bigger then the calyx. Fruits are 
cylindrical and divergent follicles, containing the many oblong, flat and 
whitish pubescent seeds [116]. Roots are reddish-brown, woody and aromatic. 
Hemidesmus indicus var. indicus Hemidesmus indicus var. pubescens 




Species: Hemidesmus indicus /Hemidesmus 
pubescens  




HI roots store a huge mixture of biologically active compounds and 
represents the active part of HI. In traditional medicine, HI was assimilated in 
the form of root decoction. Thus in this thesis, aqueous extracts have been 
chosen for pharmacologic evaluations. The major constituent (91%) of HI 
extract is the 2-hydroxy 4-methoxy benzoic acid. But other important 
phytochemicals have been identified. From the highest to the lowest in 
amount, HI contains: saponins, tannins, alkaloids, flavonoids, phenols, 
coumarins and terpenoids [117]. Among the less abundant molecules found in 
the extract of HI, the most characterized are hemidesmins (coumarino-lignans) 
[118], and hemidesmosides A-C (steroidal glycosides) [119]. Of note, the two 
main variants of Hemidesmus, indicus and pubescent, don’t differ in a 
significant way in terms of constituents. HI has only a higher content of 
phenols and free amino acids and a less content of b-sitosterol and tannins 
than pubescens [120]. 
Systematical studies about the pharmacological profile of HI begun more 
than 50 years ago, and currently many in vitro, in vivo, and ex vivo 
investigations supported and demonstrated some traditional uses of HI, such 
as the anti-diarrhea and anti-dysentery properties [117,  121]. Indeed, HI was 
widely used in traditional medicine mainly to cure diarrhea and dysentery, 
but was also exploited as antibiotic, ulcer and gastric protector, neutralizer of 
snakebites and scorpion stings, blood purifier and appetite stimulant. It was 
considered a remedy for a whole variety of pathologies and diseases, such as 
sore mouth, fever, menorrhagia, post-partum recovery, headache, 
inflammation and pain, venereal diseases including syphilis and gonorrhea, 
and erectile dysfunction [120,  122]. 
However, besides the folkloristic use of HI, its chemopreventive and 
antitumor potential has been widely investigated and established. Different HI 
extracts demised hepatocyte carcinoma HepG2 (aqueous and ethanolic 
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extracts), breast cancer MCF-7, colon cancer HT29 (methanolic extract), and 
leukemia Jurkat (aqueous extract) cells. Furthermore, my research group 
headed by Professor Fimognari performed extensive studies showing HI 
decoction’s (HID’s) antileukemic activity. They demonstrated that HID has 
anti-angiogenic effects and cytotoxic and cytostatic properties on 
promyelocytic leukemia cells, while it triggered the apoptotic mitochondrial 
pathway on Jurkat cells [123,  124]. Moreover, HID enhanced the antitumor 
potential of methotrexate, 6-thioguanine and cytarabin [123]. This ability 
underlines the interesting clinical potential for HID to be used as 
complementary drug to improve the anticancer activity of traditional 
chemotherapeutic agents and allow lowering their toxicity. 
3.2. Aim of the Study 
The promising pharmacological profile and the deep knowledge about its 
antitumor potential made me choose HI as candidate for ICD studies of my 
last year of PhD. Thus, the aim of the study was to draw a systematic and 
exhaustive in vitro characterization of HID as ICD inducer. In the traditional 
medicine HI is used as a decoction. For this reason, I decided to use the human 
colon cancer dld1 cell line as cancer model. The study started with the 
evaluation of the cytotoxic and proapoptotic potential of HID on dld1 and the 
investigation about its ability to trigger oxidative and ER stress. Then specific 
ICD studies were performed and HID’s ability to provoke DAMPs trafficking 
was assessed. As I decided to work with a human model of cancer, the 
understanding of HID’s real immunogenic potential through vaccination 
experiments was not possible. To bypass this issue and directly address HID 
immunomodulatory potential, I evaluated the ability of the decoction to 
promote DCs maturation and to enhance interleukin IL1β and IL12p40 gene 
expression from monocytes obtained from healthy donors. 
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3.3.  Results and Discussion 
3.3.1. Characterization of HID 
The main phytomarkers of HID, 2-hydroxy-4-methoxybenzaldehyde, 3- 
hydroxy-4-methoxybenzaldehyde and 2-hydroxy-4-methoxybenzoic acid, 
were identified and quantified through HPLC analysis. The difference among 
the batches in the phytomarker content and pharmacological activity resulted 
not significant (data not shown). 
3.3.2. HID has Cytotoxic and Proapoptotic Potential 
The study begun with the investigation of HID concentrations needed to 
demise more than half of the tumor population. We treated dld1 with 
increasing concentration of HID for 48 h to identify doses able to cause more 
than 50% of cell death. 0.62 mg/mL, 0.93 mg/mL and 1.55 mg/mL treatments 
decreased of 52.7, 62.1 and 68.8% cell viability, respectively, compared to 
untreated cells (Figure 3.1) and were chosen to perform all the following 
experiments. 
 
Figure 3.1 Percentage of viable dld1 cells after 48 h treatment with increasing concentration of 































Then, as ICD is traditionally conceived as a particular form of apoptotic 
cell death, we investigated the cell death modalities that were engaged in 
response to HID. After 6 h, HID didn’t trigger any RCD (data not shown), 
whereas after 24 h HID-treated dld1 revealed a dose-dependent increase in the 
percentage of apoptotic cells. HID elicited apoptotic cell death at all tested 
concentrations in a dose-dependent manner. 0.93 mg/mL treatment drove 
13.8% of cells to apoptosis versus 3.3% of untreated cells, while HDI 1.55 
mg/mL induced 24.7% of apoptosis (Figure 3.2). These data are consistent with 
those published on Jurkat cells by Fimognari et al. [123] except for the extent of 
necrotic fraction that in HDI-treated dld1 were higher. This discrepancy was 
probably due to the trypsinization step needed to detach dld1 before 
performing the apoptotic assay, step that is not required for Jurkat cells since 
they grow in suspension. 
 
Figure 3.2 Percentage of viable (7AAD-/AnnV-), early apoptotic (7AAD-/AnnV+), and late 
apoptotic or secondary necrotic (7AAD+/AnnV+) cells after 24 h treatment of dld1 cells with increasing 


















































3.3.3. HID Triggers ER and Oxidative Stress 
Induction of ER stress was evaluated by monitoring the kinetics of key 
markers linked to ICD induction. I paid special attention on the PERK-eIF2α 
branch of the UPR that has been previously shown to govern danger signaling 
during ICD [125]. Thus, I evaluated the phosphorylation status of PERK and 
eIF2α, as a general readout of the transcriptional activation of the UPR. Of 
note, there is no antibody commercially available that recognizes specifically 
the phosphorylated state of human PERK for western blot, thus we use the 
molecular weight shift in SDS - PAGE as indicator of phosphorylated PERK. 
HID was able to trigger the activation of PERK pathway starting from 1 h and 
reached a peak after 3 h, while no modulation was observed after 24 h 
treatments (Data not shown). In particular, after 3 h at 1.55 mg/mL, HID 
increased phosphorylated phosphorylated PERK (p-PERK) and 
phosphorylated eIF2α (p- eIF2α) (Figure 3.3) of 3.14 and 3.89 times respect to 
untreated cells. 
 
Figure 3.3 Representative blots of at least three independent experiments analysis for eIF2α and 
(total and phosphorylated) protein levels in dld1 cells treated with HID (mg/mL). 
 
To directly link ER stress to the antitumor potential of HID, ER stress was 
prevented with specific agents before treating dld1 with HID and then 
recording viability. Attenuation of ER stress with both tauroursodeoxycholic 
acid TUDCA (general ER stress inhibitor) and AMGPERK44 (PERK-activation 
inhibitor) affected the cytotoxic activity of HID recorded after 24 h in a 
C- 0.62 0.93 1.55 C- 0.62 0.93 1.55 C- 0.62 0.93 1.55 C- 0.62 0.93 1.55
eIF2α
p-eIF2α
1 h 6 h3 h 24 h
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concentration-dependent manner, that however was not enough to restore 
complete viability. This suggests a crucial, but not exhaustive, role of ER stress 
in HID mechanism of action (Figure 3.4). More, the cytoprotective effect of 
TUDCA did not differ from the one obtained with AMGPERK44, suggesting 
the complete implication of PERK branch of the UPR. 
 
 
Figure 3.4 Percentage of viable cells after dld1 treatment with HID alone or in combination with 
TUDCA or AMGPERK44 for 24 h. * versus untreated cells; ° HID versus ER stress inhibitors, respectively 
TUDCA or AMG PERK 44. * or ° P < 0.05; °° P < 0.01; *** P < 0.001; **** P < 0.0001. Unpaired t test was 
used to calculate statistical significance of three independent experiments. 
 
As thapsigargin demonstrates, ER stress alone is not sufficient to trigger 
ICD [126], thus HID’s ability to provoke oxidative stress was examined. 
Intracellular ROS levels were recorded after 1, 3, 6 or 24 h treatment with HID 
0.62, 0.93 and 1.55 mg/mL. Oxidative stress was increased starting from 1 h in 
a concentration-dependent manner. After 3 h at all tested concentrations, ROS 
levels reached the highest level recorded. 0.62, 0.93 and 1.55 mg/mL raised 
intracellular ROS content 5.08, 5.79 and 7.38 times, respectively, compared to 
















































above those recorded for untreated cells, 6 and 24 h treatments showed a 
descending trend of ROS levels (Figure 3.5). 
These data show that HID triggers ROS and ER stress following the same 
time tendency. This is an interesting result since ICD is a stressor-dependent 
kind of apoptosis, founded on ROS-based and, at least simultaneous, ER stress 
[43,  48,  127]. 
 
 
Figure 3.5 ROS fold increase in HID-treated cells for 1, 3, 6 or 24 h compared to untreated cells. 
3.3.4. HID Induces DAMP’s Trafficking 
HID was tested in a time-course experimental setting for its ability to 
endorse the main in vitro hallmarks of ICD i.e. the surface exposure of CLR and 
HSP70 and the secretion of ATP and HMGB1. 
We monitored surface exposure of CLR and HSP70 through flow 





































































after 3 h treatments with HID 0.93 and 1.55 mg/mL, while after 6 h all tested 
concentrations triggered CLR mobilization. The higher ecto-CLR value was 
reached after 6 h of 1.55 mg/mL with a fold increase of 1.37, compared to 
untreated cells (Figure 3.6 A), a very similar value to that observed for 
mitoxantrone, a bona fide type I ICD inducer, in T24 cells after 4 h of incubation 
[48]. At 24 h post treatment, ecto-CLR was still higher than that recorded for 
untreated cells, but at a lesser extent than before (Figure 3.6 A). The lowest 
tested concentration of HID did not modulate HSP70 trafficking at any time 
point, while both 0.93 and 1.55 mg/mL favored its mobilization in a dose- and 
time-dependent fashion. After 24 h of treatment, the highest tested 
concentration induced the highest increase in HSP70 MFI that was 1.42 times 
higher than that recorded for untreated cells (Figure 3.6 B).  
HID provoked ATP secretion at all tested concentrations and time point 
analyzed (3, 6 and 24 h). After 3 h, it induced the highest rise, increasing ATP 
levels in the extracellular medium of 36 and 73 times for 0.93 and 1.55 mg/mL, 
respectively (Figure 3.6 C). The entity of this increase reminds that of Hyp-
PDT in human bladder carcinoma T24 cell line at 1 h post treatment [48]. After 
48 h of HDI treatments, HMGB1 was mobilized from the cytoplasm to the 
extracellular matrix, as showed in (Figure 3.6 D). 
Of note, after 3 h treatment, both HID-mediated ER and oxidative stress 





Figure 3.6 DAMPs trafficking panel: ecto-CRT (A), ecto-HSP70 (B) expression in nonpermeabilized 
cells after HDI-dld1 treatment at different time points; ATP secretion following HDI treatment after 
different time points (C); dld1 cells untreated and following 48 h treatment with HID 0.6 mg/mL were 
stained with anti-HMGB1 (red) and DAPI (blue) for nuclei counterstaining. Magnifications 100x, scale 
bar 10 µm (D). * P < 0.05; **** P < 0.0001 
Even if ICD inducers do not share fixed patterns in terms of DAMP’s 
trafficking (or common pathways have not been discovered yet), Oliver Kepp	
[128] and its group found a sort of spatiotemporal code through which DAMPs 
exert their immunological awakening. Chemotherapy agents exert a cytotoxic 
effect on cells that immediately elect whether cell death will be immunogenic, 
silent or tolerogenic [129]. Right after the damaging stimulus, cells activate 
their defensive repair mechanisms. During this phase cells are already alerted 
to face a potential identification and elimination of demising cells. During ICD, 
CRT translocation is usually the first “eat me” signal emitted, most likely 
balanced with following “don’t eat me” signals. Ecto-CLR positioned on a 





































































































































HID - treated dld1
	
80	
provide, at least in part, the switch to a cognate immune response by APCs 
instead of a silent deletion of demising cancer cells by macrophages [128]. 
Moreover, HSP70 is enrolled during the central response of dying cells to 
stress. The main role hypothesized for it is to break the tolerance of immune 
system acting as antigen chaperon and favoring DC-tumor cells adhesion [129-
131]. Nevertheless, the mobilization of HSP70 (and other HSPs in general) 
arises rather late as compared to CRT and could consequently play an 
additional/synergistic role to CRT primary “eat me” signal favoring DCs 
uptake and process of the antigen. The talk between dying cells and DC (or 
APC in general) is complex and opposite messages can reach the immune cells	
[128]. This fact makes the spatiotemporal code essential for a full-triggered 
immune response, and explains the late release of HMGB1, that could be 
linked to the same iDC that incorporates antigen from dying cells thanks to 
CLR and HSPs. This intricate sequence represents a code that dying cells 
follow to counteract all signals that potentially silence the immune response	
[128]. 
Hyp-PDT causes early, pre-apoptotic induction of ecto-CRT and actives 
pre-apoptotic secretion of ATP in stressed cells, overlapping PERK-
orchestrated pathways. These events are tailed by late apoptotic mobilization 
of HSP70 and HSP90	[48]. Mitoxantrone and oxalilplatin prompt pre-apoptotic 
ecto-CLR, early apoptotic secreted ATP, mid to late ecto-HSP70 and late 
apoptotic passive release of HMGBI	 [54,  132,  133]. Shikonin, for its part, 
induces early to mid apoptotic ecto-CRT and ecto-HSP70	 [6,  134]. Taken 
together, our data perfectly describe the profile of DAMPs-trafficking 
triggered by an ICD inducer. They indicate that HID provokes pre-apoptotic 
release of ATP and exposure of CLR, early- and mid-apoptotic exposure of 
HSP70 and a subsequent release of HMGB1 at the late stages of dying cells. 
Further studies are needed to assess which type of ICD inducer HID is. 
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However, except for ATP, the entity of HID- modulated DAMPs trafficking 
reminds that induced by mitoxantrone, presuming HID to be a type I ICD 
inducer. Of note, HID-driven ER stress is only mild intense. An interesting 
future approach would be to evaluate the ability of an ER stressor, such as 
tunicamycin or thapsigargin, to increase HID-mediated DAMPs trafficking 
that presumably would translate in a greater immunogenic potential. 
Altogether, these data are interesting for many reasons. On one hand, 
HID is able to deploy four different DAMPs jointly, increasing the chances of a 
positive immunogenic outcome since the potency of the immune response 
depends on the complexity and intensity of the emitted DAMPs. Indeed, as 
above mentioned, each danger signal has a different role in the stimulation of 
immune system and a concurrent activation increases the chances to exert full 
immunogenicity. CLR is a strong “eat me” signal and mediates tumor 
immunogenicity [35,  48,  135,  136]; HSP70 recalls monocytes and neutrophils 
and fosters DC maturation and NK cell activation [47,  48,  133,  136,  137]; ATP 
is a “find me” signal, causes IL-1β release from DC and mediates, for instance, 
mitoxantrone- and oxaliplatin-induced antitumor immunity [32,  42,  48,  133]; 
HMGB1 acts as a potent cytokine, induces DC maturation and attracts various 
immune cells [47,  133,  138-141]. On the whole, those DAMPs build the 
biological ability to trigger ICD. On the other hand, conversely from 
anthracyclines, HID stimulates all DAMPs at the same concentrations (0.93 and 
1.55 mg/mL), thereby incorporating the rise of these critical immunogenic 
signals within a single therapeutic set-up, and indicate an easier prospective of 
clinical use [48]. 
3.3.5. HID Promotes DC’s Maturation and Increases ILs 
Expression on Human Monocytes 
HID induces signature of danger signaling in colon cancer cells. Then, 
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we investigated the direct interactions of such treated colon cancer cells with 
key immune cells. 
DCs are able to recognize and present antigens to different cell types such 
as CD4+ helper T cells, CD8+ cytotoxic T lymphocytes and B cells, hence 
representing the connection between innate and adaptive immune system 
[142]. Upon activation, DCs proceed through the maturation process during 
which they lose their phagocytizing ability, increase the surface expression of 
MHC class I and class II peptide complexes and the expression of 
costimulatory molecules (CD80 and CD86, among others), and secrete 
proinflammatory cytokines. Then, the mature DCs migrate into draining 
lymph nodes. All these phenotypic transformations allow DCs being in contact 
with nai ̈ve T cells, priming the T-cell-mediated immune response. TLRs are the 
best-characterized PRRs on DCs surface and promote DCs activations when 
the designated ligands bind them. As already mentioned, DAMPs stimulate 
the immune system through the interaction with DCs and TLRs [143]. For 
instance, ecto-CLR enables the uptake of dying cells by DCs, stimulating 
their engulfment	 [32], while HMGB1 binds TLR4 and promotes antigen 
processing of the phagocytic cargo [4]. HSP70 is a DCs chemoattractant and 
promotes their maturation via TLR4 signaling. Indeed, TLR4 activation 
promotes the synthesis of pro-IL-1β, the precursor of interleukin [128]. ATP is 
another crucial DC activator. It triggers the NLRP3 inflammasome in DCs 
inducing, as well, IL-1β release and the consequent priming of cytotoxic T cells	
[143]. 
We cultivated C14-derived immature DCs (iDCs) for 24 h in the 48 h-
HID-treated-dld1 culture medium and measured the phenotypic maturation, 
(i.e. increased surface expression of CD80, CD83, and CD86) and functional 
stimulation (i.e. amplified production of Ilβ by DCs). LPS treatment of iDCs 
was used as a positive control to test the maturation potency of iDCs. HID-
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treated dld1 cells induced DC-maturation, as demonstrated by the increase in 
all clusters of differentiation analyzed (Figure 3.7 A).  
Then, we quantified IL-1β secretion in the conditioned media used in the 
DC maturation analysis experiments. The expression of IL1β and IL12p40 
genes were both enhanced. Remarkably, those treatments resulted in the 
modulation of cytokine gene expression and phenotypic profiles of iDC similar 
to that induced by LPS and demonstrated the functional activations of DCs 
(Figure 3.7 B and C). 
To make sure that the immunostimulant profile of HID-treated dying 
dld1 would not be mistaken for a direct immunostimulant effect of HID, we 
investigated the antigenic potential of HID to be recognized by T cells. Total 
peripheral blood mononuclear cells (PBMCs) from healthy donors were 
cultured in presence of increasing concentrations of HID. Lymphoproliferative 
response was analyzed by 3H-thymidine incorporation on day 7. Data from 4 
different experiments with cells from healthy donors indicate that HID did not 
per se induce T-cell proliferation (Figure 3.7 D), giving one more evidence of 





Figure 3.7 CD80, CD86 and CD83 expression in DC from a representative donor, untreated or 
following 48 h treatment with dld1 supernatant obtained after HID treatment. LPS-treated cells were 
used as positive control (A). Example of IL1β expression in one donor, representative of three different 
experiments, performed with similar results. GAPDH gene expression was used as control (B). IL12p40 
expression on DCs incubated for 48 h with supernatant of HID-treated cells, normalized on untreated 
cells (mean of 3 experiments). GAPDH was used as control housekeeping gene (C). CD8+ T Cell 























































































































During the last year of my PhD I extensively characterized the HID 
profile as ICD inducer on human colon cancer cells. After assessing the 
apoptotic potential of HID, I demonstrated its ability to trigger both ER and 
oxidative stress with the same kinetics and I correlated those two events with 
the cytotoxic potential of HID. I discovered that the immunogenicity of HID-
mediated cell death is governed by the preapoptotic mobilization on the outer 
cellular membrane and secretion of CLR and ATP, respectively, coupled with 
HSP70 translocation during the early phases of apoptosis and the late release 
of HMGB1. The interaction of immature DCs with immunogenic tumor dying 
cells led to an increase in the expression of maturation-associated markers on 
DCs and the secretion of inflammatory IL1β and IL12p40. Furthermore, I 
confirmed that the stimulation of the immune system was elicit by the HID-
treated dying cancer cells and not by HID itself, since HID didn’t exert any 
direct effect on T-cells. At this point, to confirm HID factual endogenous 
vaccine-like potential, it would be interesting translating these results into a 
murine cell line in order to be able to perform in vivo studies. 
This was the first report where the ability of a botanical drug to trigger all 
hallmarks of ICD, comprised DCs activation and maturation, was 
demonstrated. Different synthetic chemotherapeutic drugs induce ICD and 
were characterized in detail [5]. In contrast, there is a paucity of data regarding 
natural products of potential clinical relevance	 [6]. A variety of natural 
anticancer compounds have been successfully characterized	 [7,  8]. However, 
their immunogenic potential has not been analyzed in comparable detail	 [9]. 
Furthermore, toxicity seems not to be an issue related to HID use. Indeed, 
neither lethality nor conspicuous alteration in mice behavior was noticed after 
root powder suspension was administered to test acute toxicity on Swiss 
	
86	
albino mice [121]. Furthermore, the LD50 (the amount of a toxic sufficient to kill 
50 percent of a population) measured for liver and kidney is at least 130 times 
higher than the concentrations used in this study	 [117]. An ethanolic root 
extract of HI prevented cytogenetic damage triggered by cisplatin on 
lymphocytes [144]. The impact of my studies could be enormous in the view of 
HID as adjuvant of other traditional antitumor agents. HID have synergistic 
antileukemia potential with 6-thioguanine, cytarabine and methotrexate, and 
interesting could be to try to increase HID immunological stimulation in a 
combination therapy with a pure ER stressor. The latter agent could increase 
the entity of HID immune response potentially reaching the effect of a type II 
ICD inducer. Otherwise HID could be used with the aim of increasing 
responsiveness to other immunological anticancer therapy, such as the use of 
monoclonal antibodies that target immunological checkpoints. 
On the whole, the antitumor profile of HID that emerges from this study 
provides a clear rationale for the design of in vivo experiments and rightfully 
paved the way for pilot clinical trials. 
3.5. Material and Methods 
3.5.1. Plant Decoction and Extract Preparation 
 HI (voucher #MAPL/20/178) was collected from Ram Bagh (Rajasthan, 
India), and authenticated by Dr. MR Uniyal, Maharishi Ayurveda Product 
Ltd., Noida, India. The plant decoction was prepared according to the method 
described in the Ayurvedic Pharmacopoeia of India [145]. Briefly, 10 g of 
grinded roots of HI were mixed with 300 mL of boiling water, allowing the 
volume of water to reach 75 mL. The decoction was filtered, lyophilized, 
aliquoted and stored at room temperature. Immediately before the assays, the 
samples were resuspended in water in a 31 g: 1000 mL ratio and centrifuged at 
4000 rpm for 5 minutes to discard any insoluble material. Eventually, 
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samples were sterile-filtered when necessary. The experiments and the HPLC 
analysis were performed using this stock solution of 31 mg/mL. 
3.5.2. HPLC Analysis and Validation: 
 HID was subjected to HPLC analysis to quantify its main phytomarkers, 
namely 2- hydroxy-4-methoxybenzaldehyde (2H4MBAL), 3-hydroxy-4-
methoxybenzaldehyde (3H4MBAL) and acid 2- hydroxy-4-methoxybenzoic 
(2H4MBAC127). The reference compounds (all obtained from Sigma Aldrich) 
were used as external standards to set up and calculate appropriate calibration 
curves. The analyses were performed using a Jasco modular HPLC (Tokyo, 
Japan, model PU 2089) coupled to a diode array apparatus (MD 2010 Plus) 
linked to an injection valve with a 20 mL sampler loop. The column used was a 
Tracer Extrasil ODS2 (2560.46 cm, i.d., 5 mm) with a flow rate of 1.0 
mL/minutes. The mobile phase consisted of solvent solution B (methanol) and 
A (water/formic acid = 95:5). The gradient system adopted was characterized 
by five steps: 1, isocratic, B/30 for 15 minutes; 2, B raised progressively from 
30% to 40% at 20 minutes; 3, B then raised to 60% at 50 minutes; 4, B achieved 
80% at 55 minutes and 5, 100% at 60 minutes. Injection volume was 40.0 mL. 
Following chromatogram recording, peaks from HI samples were identified by 
comparing their UV spectra and retention time with those from the pure 
standards. The identity was also confirmed by 1H NMR on the enriched 
fraction of the compounds obtained by soxhlet extraction in CHCl3/EtOH 1:1. 
Dedicated Borwin software (Borwin ver. 1.22, JMBS Developments, Grenoble, 
France) was used to calculate peak area by integration. 
 Individual stock solutions of 2H4MBAL, 3H4MBAL and 2H4MBAC 
were prepared in water. Six different calibration levels were prepared within 
the following range: 2–20 mg/mL for 2H4MBAL, 1.5–40.0 mg/mL for 
3H4MBAL, and 1–100 mg/mL for 2H4MBAC. Each calibration solution was 
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injected into HPLC in triplicate. The calibration graphs were provided by the 
regression analysis of peak area of the analytes versus the related 
concentrations. The analysis of HI (31 mg/mL) was performed under the same 
experimental conditions. The obtained calibration graphs allowed the 
determination of the concentration of the three components. Three different 
batches of HI were tested. 
3.5.3. Cell Cultures and Treatments 
 Authenticated human colon adenocarcinoma cell line MMR-deficient, 
dld1, was purchased from ATCC. Dld1 were propagated in adhesion and 
cultured in RPMI 1640 supplemented with 10% inactivated Fetal Bovine Serum 
(FBS), 1% GlutaMAX-I, and 1% kanamycin (all purchased by Gibco-Life 
Technologies), at 37°C and 5% CO2. All cultures were tested by PCR and 
proven to be mycoplasma free prior to experimental investigations. 
 PBMCs from healthy donors (Blood donor center of the University 
Hospital of Basel) were obtained by gradient centrifugation. Both CD14+ 
monocytes and CD8+ T cells were magnetically isolated from PBMCs by using 
antibody-coated beads (Milteny Biotech) and cultured in RPMI 1640 
supplemented with 1% GlutaMAX-I, 1% non-essential amino acids (NEAA), 
1% sodium pyruvate, HEPES, 1% Kanamycin sulfate and 10% FBS (all 
purchased by Gibco-Life Technologies) for CD14+ monocytes and 5% pooled 
human AB serum for co-culture of myeloid and T cells. DC were generated in 
presence of GM-CSF and IL4, as previously described	[146]. 
 10,000 cells were seeded in 200 µL of complete medum, 58000 in 500 µL 
or 1.7x106/7 mL respectively in 96, 24 wells plates or 10 cm dishes. Cell lines 
cultured were treated with HID, oxaliplatin or etoposide at the indicated 
concentrations. To rule out a role of contaminating endotoxin in the elicitation 
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of the effects of HI polimixin B (Calbiochem) was added at 10 µg/mL to all 
cultures during cell treatment with HID. 
 For ER stress-related experiments dld-1 cells were pretreated with 
sodium tauroursodeoxycholate (TUDCA) 1 mM (Sigma Aldrich) or 
AMGPERK44 (Tocris Bioscience) 5 µM for 1 h and then co-incubated with 
increasing concentrations HID for 24 h, then viability was assessed using 4-
methylumbelliferyl heptanoate (MUH, Sigma Aldrich) that becomes highly 
fluorescent after hydrolysis of the ester linkage and, thus, measures lipase and 
esterase activity [147]. After treatment with ER stress inhibitors and HID, cells 
were washed with PBS and incubated with MUH 1 mg/mL. After 30 minutes 
of incubation at 37°C and 5% CO2, absorption at 460 nm was measured using a 
microplate reader (Tecan). 
3.5.4. Analysis of Cell Viability and Induction of Apoptosis 
 The acid phosphatase (APH) assay was used to determine dld-1 
viability. 405 nm absorbance is directly proportional to numbers of viable cells 
present in monolayers. After 48 h, cells were washed twice with PBS and then 
resuspended in 100 µL of the assay buffer [0.1 M sodium acetate, 0.1% Triton-
X-100, supplemented with 4-nitrophenyl phosphate disodium salt hexahydrate 
(N9389, Sigma Aldrich)] were added to each well. After 90 minutes incubation 
at 37°, 10 µL NaOH 1 N was added to each well and the absorption at 405 nm 
was measured within 10 minutes on a microplate analyzer. 
 To discriminate regulated form of cell death, Guava Nexin Reagent 
(Merck Millipore) was used. Through the use of 7-AAD and annexin V-
phycoerythrin, the assay allows the discrimination of apoptotic and necrotic 
events. Cells were incubated with the reagent for 20 minutes at room 




were first detached with TrypLE™ Express Enzyme (Thermofisher Scientific), 
washed twice with PBS and then incubated with the reagent. 
3.5.5. Proliferation Assay 
 Proliferation of PBMCs obtained by healthy donors was evaluated by 
3H-thymidyne incorporation. PBMCs cells were cultured for 5 days after 
treatment with HI 0.6 mg/mL-4.8 µg/mL. Cells were treated with 1 µCi/200 µL 
3H-thymidine (Amerchem) for 18h and harvested on paper filters. 3H-
thymidine uptake from PBMCs was measured in a liquid scintillation counter. 
Tubercolin PPD (Staten Serum Institute) was used as positive control for 3H-
thymidine incorporation. 
3.5.6. Detection of ROS Levels 
 ROS levels were determined after 1, 3, 6, 18 or 24 h of WSE treatment by 
using the probe 2′,7′-Dichlorofluorescin diacetate (DCFDA), which was added 
during the last 20 minutes of incubation. Hydrogen peroxide was used as 
positive control. Dld-1 cells were detached with TrypLE™ Express Enzyme 
after the reagent was added. After three washing in PBS, cellular fluorescence 
was imaged using a Leica DMLB/DFC300F fluorescence microscope (Leica 
Microsystems) equipped with an Olympus ColorviewIIIu CCD camera 
(Polyphoto). Fluorescence images (100 cells per sample from randomly 
selected fields) were digitally acquired and processed for fluorescence 
determination at the single cell level on a personal computer using the public 
domain program, Image J. Mean fluorescence values were determined by 




3.5.7. Analysis of Calreticulin, HSP70 and HSP90 Expression, and 
ATP and HMGB1 Release 
After treatment, cells were collected with TrypLE Express (Life 
Technologies), washed with PBS and with Flow Cytometry buffer (FCB) (2% 
FBS, 1% BSA in PBS), incubated for 1 hour at 4°C with primary antibodies, 
washed, and incubated for 1 hour at 4°C with secondary antibodies, if 
neecessary. After final washes, cells were incubated in FC buffer including 1 
nmol/L Sytox Red (Thermo Fisher Scientific) or Propidium iodide (PI) 0.5 
µg/mL for 15 minutes and analyzed on Attune Flow Cytometer (Life 
Technologies). The permeabilized cells were excluded from the analysis due to 
intracellular staining, and the fold changes in the mean fluorescence intensity 
(MFI) for each DAMP were analyzed.  
Fluorochrome-labeled monoclonal antibodies recognizing CD1a, CD8, 
CD14, CD16, CD83, CD80, CD86, HLA-DR were obtained from Becton 
Dickinson, PE-labeled calreticulin (1:100 dilution in FC) was obtained from 
abcam, while non-labelled Hsp70 from thermofisher (1:100 dilution in FC) and 
coupled with the Alexa Fluor 647 labelled-goat anti-mouse igg (H+L) cross-
adsorbed secondary antibody (Thermofisher Scientific) (1:100 dilution in FC). 
The appropriate antibody and specific binding was evaluated by flow 
cytometry (FACScalibur, Becton Dickinson, or Guava EasyCyte 5HT, Merck 
Millipore).  
 The kit ATPLiteTM 1step (Perkin Elmer, Waltham, MA, USA) was used 
for the detection of ATP extracellular concentration. Jurkat cells were seeded 
and treated with WSE in Hank's Balanced Salt Solution (HBSS) or complete 
medium for 6 and 24 h, respectively. At the end of incubation, supernatants 
were collected and treated with 100 µL of ATPLite 1step reagent containing 
luciferase and D-luciferin. After shaking for 2 minutes at 700 rpm using the 
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orbital microplate shaker 711/+ (Asal srl, Florence, Italy), luminescence of the 
samples was measured in a 96-well black plate using the microplate reader 
Victor X3 (Perkin Elmer).  
3.5.8. Immunofluorescence 
 Dld-1 cells were cultured in 8 well culture chambers slide (Falcon) and, 
after treatment with HID for 24 h, they were fixed with formalin 4%, 
permeabilized with methanol 90% and incubated with mouse monoclonal anti-
HMGB1 specific antibodies (Abcam), followed by incubation with goat anti-
mouse Alexa Fluor 546 secondary antibody (Invitrogen). Nuclei were 
counterstained with DAPI. Cells were examined under an Olympus BX61 
fluorescence microscope (Olympus) and images were captured by a digital 
camera and Analysis Software (Soft Imaging System GmbH) with a 20X, 60X 
or 100x magnification.  
3.5.9. Western Blot analysis 
After incubation in 10 cm dishes with various concentrations of HID for 
1, 3, 6 or 24 h cells were washed three times with cold PBS. Cells were 
subsequently scraped and collected in 1 mL of PBS and centrifuged twice, after 
which the pellet was lysed with 220 µL of Lysis buffer (NaCl 0.75 M, Triton X-
100 1:20, Tris-Cl 0.25 M and leupeptin 2 µg/mL and PMFS 100 µg/mL added 
before use). Cells were then homogenized and allowed to stand at 4°C for 30 
minutes. Cells were centrifuged at 14,000 g for 15 minutes at 4°C. Then, proteic 
lysates were collected and transferred to clean eppendorfs. 
Samples (30 µg proteins) were separated on 10% SDS-polyacrylamyde 
gels (Bio-Rad, Hercules) and electroblotted onto 0.2 µm nitrocellulose 
membranes. Membranes were incubated overnight at 4 °C with primary 
antibodies recognizing either PERK (Abcam), pPERK (aAcam), EIF2α (Cell 
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Signaling) and pEIF2 α (Cell signaling). Membranes were washed with TBS-T 
(TBS + 0.05% Tween20), and then incubated with a horseradish peroxidase 
(POD) linked anti-rabbit secondary antibody (1:2000; GE Healthcare,). 
Immunoreactive bands were visualized by enhanced chemiluminescence 
(ECL; Pierce). The same membranes were stripped and reprobed with a β-actin 
antibody (1:1000; Sigma–Aldrich) for TH or total ERK1/2 (1:1000; Cell 
Signaling) for pERK1/2. Data were analyzed by densitometry, using Quantity 
One software (Bio-Rad). Values were expressed as fold increase versus 
respective contralateral intact site. 
3.5.10. Gene Expression Analysis 
 Total cellular RNA was extracted from tumor cells, CD14+ or DCs cells 
using the RNeasyVR Mini Kit (Qiagen) and reverse transcribed using M-MLV 
reverse transcriptase (Invitrogen-Life Technologies, Lucerne, Switzerland) 
according to manufacturer’s protocol. Human IL12p40, IL1β gene expression 
was analyzed by quantitative real-time PCR using Taqman assay (Applied 
Biosystems-Life Technologies) and ABI Prism 7300 (Applied Biosystems). 
Gene expression was quantified using Ct method upon normalization with 
GADPH expression, as reference housekeeping gene. 
3.5.11. Statistical Analysis 
 All results are expressed as mean ± SEM of at least three independent 
experiments. Differences between treatments were assessed by t test or one-
way ANOVA and Dunnet or Bonferroni was used as post-tests. All statistical 
analyses were performed using GraphPad InStat 6.0 version (GraphPad 




The immune system is the best natural resource that organisms could 
deploy against cancer. Potentially it should recognize and eradicate 
transformed cells before they form a full-blown neoplasm. However, the 
complexity, the heterogeneity and the ability of tumor cells to constantly 
acquire new mutations make them able to escape immunosurveillance. This 
problem, also representing a hallmark of cancer [11], can be overcome thanks 
to the activity of some chemotherapeutic drugs that are able to break tumor 
tolerance while trigging an immunostimulant version of RCD. This particular 
type of agents, together with tumor eradication, initiates an intrinsic 
mechanism through which demising tumor cells trigger the immune system, 
create a proper lymphocyte T- induced memory, and act as an endogenous 
vaccine [133]. ICD has been discovered barely more than ten years ago and its 
huge potential has now been understood. Many chemotherapeutic drugs, 
commonly used in clinical settings induce ICD. Doxorubicin and oxaliplatin 
are the more common examples, but many others such as epirubicin, 
idarubicin, mitoxantrone, bortezomib, bleomycin, and cyclophosphamide 
induce ICD	[148]. To understand the impact that ICD inducer could have on 
cancer treatment, it’s interesting noticing that so far (November 2017) 6525 
clinical studies involve at least one above-cited molecule	[149]. Furthermore, 
the idea of combinatorial treatment between conventional antitumor drugs or 
other types of immune therapy with ICD inducers is rapidly entrenching. The 
aim of coupling ICD inducers to different anticancer strategy is to add or boost 
an immunomodulatory effect that renders therapy more efficient and avoids 
relapses	 [148]. Good evidence of this interest is the 8 clinical studies that 
investigate the additive effect of ICD inducers and checkpoint inhibitors, the 
151 clinical reports that combine ICD inducers with antitumor vaccine 
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therapies, and the 527 clinical analysis about the activity of ICD inducers 
combined with targeted antitumor therapy based on monoclonal antibodies 
[149].  
In this context, natural products are perfect candidates for combinatorial 
therapeutic strategy. Usually they are characterized by low toxicity and 
interesting pharmacological properties [55]. Indeed, talking about botanical 
drugs, their strength is exactly their complex nature that makes them a library 
of biological active compounds able to target several pathways 
simultaneously. This same strength could be considered a pitfall from the 
point of view of product standardization [123]. However, in the case of both 
botanical drugs investigated in this thesis, phytochemicals analysis clearly 
demonstrated the presence of specific phytomarkers, which can be 
conveniently used as fingerprints. 
During the three years of my PhD, I provided a comprehensive 
preclinical, in vitro study of cell death mechanisms and immunologic 
characteristics of two botanical drugs, Withania somnifera and Hemidesmus 
indicus, and one ITC derivative synthesized ad hoc in order to reach the ER, 
MG28. 
The least promising agent in terms of ICD induction was the latter 
mentioned MG28. Assuming that concurrent ER and oxidative stress are the 
sine qua non characteristics needed to trigger ICD, MG28 was synthesized with 
the rationale of directly bring a very active chemical moiety (ITC) to the ER 
and there, to induce oxidative stress. The result would have been a type II ICD 
inducer, such as Hyp-PDT, the most efficient ICD inducer so far. MG28 did not 
exert significant apoptosis on the murine colon cancer CT26 cell line. However, 
since ICD induction is tumor-specific [127], we tested MG28 on leukemia cells 
(Jurkat), as well. In this case, MG28 triggered apoptosis through both 
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intrinsic and extrinsic pathway but the data we obtained suggested a non-
implication of ROS in its mechanism of action letting us desisting from further 
studies. 
The DMSO extract of the root of Withania somnifera showed an interesting 
cytostatic and proapoptotic potential, accompanied by increased ROS levels 
and i[Ca2+] mobilization, that could suggest ER stress. The extract induces 
DAMPs trafficking, including CLR and HSP70 and 90 exposure, and ATP 
release. However, we demonstrated, as well, its aptitude to induce DNA 
damage. The profile here described pave the way for further studies to deepen 
the immunogenic profile and exclude mutagenic properties of the extract. 
The most promising and characterized botanical drug during the course 
of my studies was the aqueous decoction of Hemidesmus indicus root. I tested 
the decoction on the human colon cancer dld1 cell line. I assessed its ability to 
trigger apoptosis that resulted driven mainly by oxidative and ER stress. This 
evidence paved the way on DAMP’s trafficking studies that showed the ability 
of the decoction to trigger the mobilization of CLR, HSP70, ATP, and HMGB1, 
following the accepted spatiotemporal order necessary to trigger ICD [128]. 
Hence, we demonstrated that Hemidesmus-mediated demising cells stimulate 
DCs maturation and activation and that this activity is not elicited by 
Hemidesmus itself, but from the danger signaling that it triggers into cells 
through its cytotoxic activity. These very promising results pave the way for 
the design of clinical studies to understand its antitumor and 
immunostimolant potential, alone or in combination with other agents. 
On the whole, the knowledge of the ability of natural compounds to 
provoke ICD suggests that they could serve as new tools for therapeutic 
interventions both alone or in combination with traditional antineoplastic 
agents, and for increasing the efficacy of anticancer drugs and at the same 
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